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Escherichia coli is a favored host for rapid, scalable expression of recombinant proteins for 
academic, commercial or therapeutic use. To maximize its economic advantages, however, it 
must be coupled with robust downstream processes. These are typically composed of three or 
fewer chromatography steps that remove the majority of the host proteins to achieve a reasonable 
degree of purification. Removal of remaining impurities is often very difficult and costly due 
similarity among physicochemical properties with the target. This work implements a novel 
approach that overcomes such limitations by bridging upstream and downstream realms, that is, 
by subjecting lysed cell material to a variety of purification procedures, identifying individual 
impurities and mitigating their removal by genetic modification. 
Successful knockout of three prominent contaminants of immobilized metal affinity 
chromatography (IMAC) without detriment to cell growth or recombinant protein expression 
was demonstrated. Elution of the recombinant target was strategically manipulated with peptide 
tags that allowed purification to virtual homogeneity. Additional IMAC studies focused on the 
most problematic host proteins, those that retained binding affinity under stringent conditions. 
Two-dimensional difference gel electrophoresis discerned variation in the soluble extract pools 
loaded in IMAC and the subsequent impurities, with respect to varied levels of recombinant 
protein expression. Peptidyl-prolyl isomerase SlyD and catabolite activator protein were shown 
to be the most persistent contaminants and had greater prevalence at low target protein 
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 v 
expression. Since genetic removal of the transcription activator would negatively impact cellular 
function, I substituted specific residues to eliminate its IMAC affinity with minimal impact on its 
activity. 
I applied this integrative strategy seeking to improve performance of cheaper, non-
affinity based processes. Phosphoenolpyruvate carboxykinase and peptidase D were significant 
contaminants during serial purification of a target by hydrophobic interaction and anion 
exchange chromatography. Ribosomal protein L25 dominated non-target binding of a 
polyarginine tagged recombinant on cation exchange resin. 
With the development of comprehensive genomic manipulation in higher order species, 
such integrative approaches will be conventional in the development of coupled expression 
systems for the production of complex biologics. 
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1.0  INTRODUCTION 
In recent decades, advances in upstream technologies have dramatically improved cell culture 
scale, yield, and performance. Recombinant DNA techniques, hybridoma technologies, 
mammalian cell culturing, metabolic engineering, and fermentation improvements have 
permitted large-scale production of biological products, whether it be proteins for diagnostic or 
research interest, vaccine products, monoclonal antibodies, or biologic therapeutics.1-3 These 
advances were in part a response to the ever-increasing market for biologics, which was valued 
at $149 billion in 2010 and projected to reach $239 billion by 2015.4 As a result, a perceived 
shift has occurred where the manufacturing steps limiting productivity are now in the 
downstream phase, in which chromatographic separation remains the cornerstone of 
bioprocessing in both industry and academia. While affinity chromatography methods in 
particular are renowned for their exceptional resolving power, their efficiency suffers at 
production scales required to process the high volumes and product titers attained upstream.5 
Research efforts have focused on cutting material costs, improving productivity at large scale, 
and developing robust, generic separation steps in an effort to quicken time-to-clinic and 
market.6, 7 Since downstream processes account for 50-80% of total manufacturing costs, efforts 
to ameliorate purification of high-value, high-quality products are critical to success in the 
biopharmaceutical industry.8-11 
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1.1 GENERAL BACKGROUND AND PRINCIPLES OF PROTEIN PURIFICATION 
For comprehensive understanding of protein purification and its principles, downstream 
processing itself must be viewed in the full context of manufacturing. Generation of complex 
cellular material occurs in the upstream phase, in which cell lines are engineered to produce a 
protein of interest and methodically cultivated in successively larger volumes of growth media. 
The goal is to maintain the conditions that generate the highest possible number of viable cells in 
the shortest time possible to achieve an optimum rate of protein productivity. This is 
accomplished through a variety of means. Controlled nutrient feeding strategies can mitigate 
formation of unwanted byproducts like acetic acid to reach high cell densities and product 
formation.12 The cell line or bacterial strain itself is customarily selected for superior gene 
expression and designed to be deficient in proteases that can inactivate the product. The product 
may be expressed as part of a protein fusion with signal peptides or chaperonins/foldases to 
promote its export from the cell membrane or to ensure folding into its proper soluble form, 
respectively. With empirical testing, these upstream strategies can be implemented to select for 
the ideal host system. Conversely, downstream processing relies on the exploitation of 
differences among physicochemical properties of the cell components and cannot be selected for 
in a similar manner.13 Instead, general principles of purification guide the investigator through 
careful deliberation in choosing, testing, and refining a separation scheme. 
The initial considerations address the general goals of the purification. What is the 
intended use of the protein? What is the nature of the source material? What is the desired 
purity? Are there safety concerns related to the source material that might require complete 
separation of a component (e.g. bacterial endotoxins)? Answers to these questions dictate the 
desired level of purity and shed light on the number and nature of the purification steps. The 
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specific number of steps is critical for one reason: some amount of product will be lost in each 
step of the process. If each step has a yield of 80% for example, in three steps the total amount of 
product recovered will be about half of what was made upstream. For high-value products, step 
yields integrally affect cost efficiency. To maximize resolving power of each step, they should 
exploit the disparities among different physical or chemical properties, such as size, surface 
charge distribution, hydrophobicity, or affinities to specific ligands or functional groups. Such 
steps are said to be orthogonal to one another. With optimized orthogonal separations, proteins 
can typically be resolved to the desired purity with high yield in four or less steps. 
After concluding the upstream phase, when the cultures have run their course, the 
working material for separation must be prepared. At this stage, sample extraction, clarification 
and stabilization are the primary goals. As is often the case, the protein of interest may reside 
within the membrane of the cell, so the sample must be extracted. For proteins that are exported 
into the culture medium, cell disruption is obviously unwanted. When cells are lysed by enzyme 
treatment, pressure or sonication for example, particulate matter in the solution must be 
thoroughly clarified from the sample since it is not compatible with column separation 
techniques later in the scheme. Clarification by centrifugation then filtration is common at small 
scales of production. The product may also be clarified by precipitation, whether by ammonium 
sulfate, polyethyleneimine or other means. Knowledge of the product with respect to 
temperature, pH and ionic strength stability is important in preventing permanent inactivation.  
The protein of interest is next captured from the clarified, complex cell lysate and 
simultaneously separates from the most plentiful contaminants. It is commonplace to pass this 
material directly over a compatible chromatography resin that emphasizes high product yield and 
capacity, often to the sacrifice of resolution. For affinity chromatography methods with superior 
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resolving power like immobilized metal affinity chromatography (IMAC), however, this step can 
purify the target protein to an intermediate degree as well. In bind-and-elute mode, the total 
elution volume that contains the protein of interest should be less than the loading material, 
which effectively concentrates it.  
Schemes that capture the target with less resolving power, as with ion exchange 
chromatography (IEX) for example, must use a complementary step for enhanced purification. 
Hydrophobic interaction (HIC), affinity, and IEX of the opposite charge if used again (cation or 
anion exchange) are the principal intermediate stages in downstream processing. This is chiefly 
due to their ability to resolve differences in physicochemical properties, often even among 
differing protein species from the same gene. If the desired purity level is not met by this stage, a 
final polishing step is needed to remove any remaining trace contaminants, often on the basis of 
size (gel filtration) or surface charge. 
IMAC was introduced by Porath and colleagues in 1975.14 A complex, clarified protein 
mixture is passed over a packed column of porous matrix, typically highly cross-linked agarose, 
with covalently functionalized metal chelating groups such as nitrilotriacetic acid (NTA). 
Immobilized nickel resins are widely commercial, although purifications are also carried out on 
immobilized cobalt, zinc, and copper. While immobilized, the metal ion is still free to covalently 
coordinate with an electron-donating base, such as the aromatic nitrogen in the imidazole group 
of a histidine residue, the strongest retaining amino acid.15 For this reason, loading material is 
typically prepared in the presence of a low concentration of imidazole and a sufficient level of 
sodium chloride to curtail weak and nonspecific interactions, respectively. Peptide tags 
containing histidine are frequently used to endow a target protein with metal-binding affinity for 
rapid purification, the nuances of which have been extensively reviewed.16-30 Bound proteins are 
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typically eluted by increasing imidazole concentrations in the mobile phase or by lowering the 
pH. Since imidazole competes with histidines for binding sites, higher imidazole concentrations 
shift the equilibrium of binding such that proteins will elute. Decreasing the pH changes protein 
residue ionization, lowering its potential to donate an electron and thus interact with the 
immobilized ion. High target protein capacity, specificity, and column operation under mild 
conditions are just few of IMAC’s many advantages. Further details for discussion on IMAC 
characterization and applications may be found here.14, 15, 31-39 
Ion exchange chromatography is perhaps the most widely utilized chromatography 
operation for protein separation. Electrostatic interactions between proteins and the charged 
matrix give separation based on differences in their net surface charges and their distribution. 
The mechanism is therefore not only determined by protein sequence and structure, but also 
highly influenced by matrix type and mobile phase pH and ionic strength.40-42 Anion exchange 
chromatography (AEX), which captures negatively charged species, and cation exchange (CEX) 
that captures positive species, are versatile in their use and purpose as they often can be useful at 
any stage in purification.2, 9, 43-48 A CEX application of particular interest is the use of 
polyarginine peptide tags to endow a protein with strong, localized positive charges, allowing 
protein retention at a pH that would otherwise result in its flow-through.49-59 Bound proteins are 
typically eluted by increasing the salt concentration. Although this technique has been 
successful, it is more protein-dependent than histidine-tagged IMAC separations since retention 
is fundamentally reliant on electrostatic interactions. 
Hydrophobic interaction is a chromatography method that permits interaction between 
non-polar residues of a protein with a porous matrix functionalized with hydrophobic groups, 
making it technique orthogonal to both affinity and ion exchange. The amount of a kosmotropic 
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agent in solution, that is a salt such as ammonium sulfate that promotes stable intermolecular 
interactions, determines the binding and elution conditions. Fundamentally, under low salt 
conditions, water molecules that surround proteins and non-polar ligands have a “shielding 
effect” on their interaction. As the buffer salt concentration increases, however, the salts strongly 
interact with the water molecules, leaving less water available to shield protein-ligand 
interactions. It is then thermodynamically favorable for hydrophobic residues to interact with the 
ligands since there is a gain in entropy from the change in water molecule structure. Desorption 
is thus achieved by reducing the salt concentration. The discovery of these HIC principles are 
reviewed in a comprehensive guide put forth by Amersham Pharmacia.60 Mobile phase pH is less 
influential on HIC than in IEX or IMAC, having only subtle effect on protein retention within 
the pH range 5-8.5.60, 61 Therefore at room temperature with a given column and salt type, salt 
concentration is the variable for tailoring protein purification. The technique is commonly used 
to separate protein aggregate species from monomeric forms,62 serum proteins,63 membrane-
bound proteins,64 and recombinant proteins65 in industrial or academic laboratories.66, 67 
Although purification strategies have long favored packed-bed chromatography methods, 
they are limited by high costs, low throughput and cumbersome scale-up.68 To this end, some 
researchers are fervently seeking alternatives to chromatographic separations,5 such as charged 
ultrafiltration membranes,69, 70 crystallization,71, 72 aqueous two-phase partitioning.73, 74 But it is 
the applications that require the utmost resolving power to produce highly pure biologics such as 
those for therapeutic use when chromatography is preferred, though formidable technical 
challenges must be overcome. As mentioned, the field of biotechnology was spurred by further 
understanding of host expression organisms and recombinant DNA technologies. Accordingly, 
some proteins may be expressed to very high levels in E. coli.12, 75-89 Exceptionally high levels 
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will result in the formation of insoluble inclusion bodies that require renaturation procedures that 
diminish recovery, putting emphasis on expressing soluble, stable target proteins. But often high-
value proteins are present only at low concentrations in cell lysate mixtures composed of a 
myriad of impurities.3 Target proteins present at low feed concentrations in complex mixtures are 
challenging to resolve. The critical operating parameters of each downstream step must be 
systematically optimized. Maintaining conditions within a target’s ‘window of stability’ with 
regard to pH, temperature, ionic strength and exposure to chemical substrates presents more 
constraints. And integrating a combination of downstream operations is itself an undertaking. 
But perhaps the most challenging aspect of bioprocess development is the presence of host cell 
proteins with physicochemical properties that are nearly indistinguishable from the target 
protein, making their separation exceptionally difficult. This nearly always occurs in a given 
purification even when the target protein is endowed with unusual or non-native properties. The 
general lack of reliable and relevant information on such contaminants is thus a costly 
shortcoming. This dearth of information is largely due to the fact that the contaminants 
themselves are inherently specific to the host organism itself, the downstream processes selected, 
and to a lesser extent the target expressed.  
It is precisely this latter challenge that the work presented in this dissertation addresses. 
An ideal plan of action would be one that not only uncovers the comprehensive physicochemical 
information about the contaminating host proteins relevant to specific downstream process, but 
one that also entirely eliminates their downstream burden without additional steps. For many 
applications, this is an ambitious goal indeed, and one that will require unique approaches. 
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1.2 A RATIONAL PURIFICATION STRATEGY THAT BRIDGES THE UPSTREAM 
AND DOWNSTREAM REALMS 
In the last decade, techniques common in the field of proteomics, the large-scale study of an 
organism’s proteins, have become more readily utilized to address certain upstream 
biotechnology considerations such as how the host cell metabolism fluctuates in response to 
recombinant protein expression or changing fermentation conditions. But only in the last few 
years have techniques that couple high throughput protein resolution and mass spectrometry been 
applied to enhance downstream process development. It is important to understand these 
technologies and how they can provide powerful insight to both the upstream and downstream 
realms. Only then can they be appropriately utilized to spur novel solutions to difficult problems 
that arise in protein purification. 
Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) is a powerful resolving 
technique that couples isoelectric focusing (IEF) that separates proteins on the basis of net charge 
in the first dimension with conventional electrophoresis for separation by mass in the second 
dimension. From a sample taken from the culture containing a living host undergoing 
fermentation for example, 2D-PAGE can give a comprehensive view of the physiological state of 
the cell. In 2001, Champion and colleagues performed this analysis of E. coli at the completion 
of four different high-cell-density fermentation processes in which differing biopharmaceutical 
products were expressed.90 Proteins were visualized and identified to assess how the cell 
responds to the fermentation conditions at the end of the growth cycle when much of the 
recombinant products are expressed. Reproducibility of the protein profile, for example, would 
lend credence to the robustness of the fermentation. While this might be interpreted as an 
upstream concern, this analysis also addresses if the majority of immunogenic host proteins are 
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consistently present in all fermentation processes. If so, it would be feasible to develop a single, 
generic immunoassay to quantitatively determine sample content of host cell protein (HCP). 
Clearance of which is a critical measure of downstream separation performance. Indeed, the 
study determined that the protein profiles were 85-90% similar across all fermentations. This 
demonstrates that understanding protein profile differences upon changes in upstream conditions 
is of vital interest to downstream process development. 
Dürrschmid and colleagues coupled RNA microarray analysis with difference gel 
electrophoresis to monitor the transcriptome and proteome to gain insight into E. coli stress 
response mechanisms, the impact of inducer IPTG and again the profile consistency after 
expression of two different recombinant products.91 Difference gel electrophoresis (DIGE) is a 
technique similar to 2D-PAGE except protein samples from different sources are independently 
labeled with fluorescent dyes, pooled together and then co-migrated on the same gel to eliminate 
variations. The dyes themselves only minimally influence migration behavior and upon imaging 
using excitation wavelengths pertaining to each dye coupled with statistical analysis, changes in 
individual protein expression across conditions can be determined. Here it was important that the 
investigators used tightly controlled fermentation conditions to give the best representative, 
homogeneous cell material for accurate transcript and proteomic data. The observed decrease in 
energy-generating and respiratory chain genes lead to the conclusion that electron transfer via the 
membrane was impaired due to high expression of recombinant products; and further that 
breakdown of the proton motive force induced expression of cytoplasmic heat shock proteins. In 
all, 62 genes and only seven proteins were consistently expressed due to recombinant production. 
This not only gives rise to needed stress markers for upstream monitoring, but also gives insight 
on the proteins that one may encounter downstream, regardless of the biologic product. 
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In a similar study carried out by Aldor and colleagues, proteomic analysis of high-cell-
density E. coli fermentation helped improve the yield of a recombinant humanized antibody 
fragment.92 In E. coli, antibody fragments are expressed in the cytosol, but secreted into the 
periplasm for assembly into a soluble form. Distinguishing from changes in protein expression 
due to culture conditions with those from biologic production, the investigators showed that 
synthesis of the stress protein PspA was strongly correlated with recombinant synthesis. The cell 
poorly assembled the antibody, with much of the heavy and light chain products accumulating 
independently. By inducing another plasmid expressing PspA before induction of the antibody in 
a preventative maintenance approach, a moderate increase in soluble antibody fragment yield 
was observed, which they speculated was due to PspA increasing transport efficiency through an 
alternative pathway. The downstream implications here are also important. Cells that produce 
biologics less prone to aggregation and are more efficiently assembled will not burden separation 
steps with as much malformed protein with properties similar to the target.  
It must be stressed again that these techniques, which effectively and rapidly expose 
cellular processes and their components, have major influences on the success of recombinant 
biologic production. They present targets for bioprocess improvement that could not be readily 
apparent to an investigator a priori. This power has only recently been harnessed to validate 
development of purifications schemes directly. 
Jin and collaborators applied DIGE analysis in Chinese Hamster Ovary (CHO) cells to 
detect profile changes in secreted HCPs with respect to: culture media; bioreactor control 
strategies like temperature shifting; feeding strategy; and cell viability.93 In mammalian hosts, 
biologics like monoclonal antibodies are secreted into the culture medium along with other 
proteins and the cytosolic contents of lysed cells. Incidentally, HCP differences between 
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monoclonal antibody producing and null cell cultures were minimal; confirming that use of cell 
not producing an antibody to generate immunoassay reagents (e.g. for the detection of HCP) is 
acceptable. It should be noted that while immunoassays provide sensitive measurements 
regarding unwanted protein content, 2D-PAGE or DIGE coupled with identification tools reveal 
physicochemical properties of individual protein species. Not surprisingly, differences in cell 
viability generated the most significant changes to the HCP profile. This was supported by a 
study by Grzeskowiak and colleagues, which found that cell viability had more influence on 
HCP profile than the CHO expression clone itself.94 In that work, DIGE was also used to confirm 
that the chosen IgG1 antibody purification scheme was robust enough to compensate for 
variations upstream, demonstrating that DIGE was a complementary tool to semi-quantitatively 
track impurities and monitor product quality downstream.  
The use of DIGE as a quantitative quality control measure provides a nice segue to a 
comment on “design space.” The term is defined by the FDA as “the multi-dimensional 
combination and interaction of input variables that have been demonstrated to provide an 
assurance of quality.”95 Understanding of the design space is one of the primary components of 
the “Quality by Design” (QbD) paradigm, which is an imperative adopted by the FDA that 
expects quality to be built into a process rather than testing product quality after a process. Other 
QbD components are understanding the relationship between the process and the critical quality 
attributes (CQAs) of the product and the influence CQAs have on the product’s clinical 
properties.96 The proteome-defining technologies discussed in this chapter can directly contribute 
to QbD by defining the design space of upstream or downstream processes. 
Modifications to 2D-PAGE can provide useful predictors of downstream behavior as 
well. Despite how well established IEX is as a purification tool, for example, specific knowledge 
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of individual protein behavior on the chromatographic media is still limited. IEX interactions are 
complicated by hydrophobic and hydrogen bonding interactions, or protein-protein associations 
that may lead to unexpected behavior. Tools such as titration curve analysis have done little to 
predict elution behavior. Now, in general practice, IEF uses reducing and denaturing conditions 
so proteins can be migrated in a linear form. But IEF can be modified to allow resolution under 
native, non-reducing conditions akin to though used during IEX.97 Migration of proteins based 
on their “functional pI” could roughly anticipate its chromatographic behavior. 
The development of predictor tools for the downstream, however, is not new. Not long 
after the advent of therapeutic recombinant human insulin and modern biotechnology itself, 
some efforts were focused on developing predictive, or expert systems to optimize downstream 
processing trains not just based on traditional heuristics, but the physicochemical properties of 
prevalent contaminants. Leser and Asenjo gave an excellent review of this early work in 1992.98 
They stressed the need to define the “biochemical and thermodynamic properties of the major 
contaminants” in the starting material. Basic properties of thirteen prevalent contaminants in the 
E. coli lysate were catalogued and used as model inputs to estimate non-affinity column retention 
times; thus predicting which steps to use and in what order. Although these expert systems 
displayed robustness to slight variations in physicochemical data, later experimental validation of 
target purity significantly deviated from predicted values.99, 100 
While there may not be a current need to improve the practicality of expert systems in 
today’s industry, the demand to establish the process-relevant physicochemical properties of host 
cell proteins remains. The proteomic technologies discussed are filling that void. Prior works by 
our group and collaborators have used 2D-PAGE and mass spectrometry to define HCPs that 
contaminate different column operations. Cai and colleagues emphasized the use of proteomic 
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routines to impact bioprocess development by characterizing HCPs in cobalt IMAC 101. Their 
group has also identified E. coli HCPs that bind to both IMAC and HIC columns under relevant 
conditions.102 Similar work has elucidated proteins that commonly diminish IMAC 
performance.103, 104 Careful structural analysis of individual protein contaminants can only result 
from such profiling work. The IMAC binder triosephosphate isomerase (TPI) is an enzyme that 
plays an important role in glycolysis since without it, half of the available carbon from glucose 
would divert away from central metabolism. Unpublished work has established that three point 
mutations in TPI can abolish its affinity for IMAC metals while maintaining glycolysis (Beitle, 
personal communication). Work by Humphreys and collaborators on the expression and 
purification of Fab’ antibody fragments from E. coli periplasm had a similar outcome.55 Under 
the IEX conditions, co-purification of the periplasmic phosphate binding protein PhoS/PstS 
presented a significant challenge. While retaining cellular function, the IEX affinity was 
sufficiently altered by the addition of six C-terminal aspartic acid residues and select lysine 
residues substituted with glutamic acid, ultimately removing the need for additional purification 
steps. 
In this thesis I address specific challenges in protein purification using an integrated 
approach (Figure 1.1), of applying the high resolving power, semi-quantitative analysis, and in-
depth protein information gained by 2D-PAGE, DIGE and mass spectrometry to the study of 
host cell protein clearance during recombinant protein purification in E. coli.  
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Figure 1.1. Schematic of the general workflow used to modify host strains for improved 
downstream efficiency.  
Bacterial pellets are grown in shake flask cultures, centrifuged, then resuspended in a suitable 
buffer for cell lysis and chromatography. Whole cells are lysed by sonication then debris is 
centrifuged. The clarified lysate (supernatant) is used for the chromatography operation of choice 
and fractionated protein pools are prepared for 1D or 2D gel analysis. Protein identities are 
determined from the gel spots by MALDI-TOF-MS and information on the contaminants is used 
to make rational modifications to the host genome. 
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2.0  MATERIALS AND METHODS 
2.1 IMAC STUDIES 
2.1.1 DNA techniques, strains and plasmids 
E. coli BL21 was used for chromosomal knockout of cyoA, yfbG and adhP. Mutants were 
generated using the Quick and Easy E. coli Gene Deletion Kit (Gene Bridges, Heidelberg, 
Germany) according to the manual. Strains, plasmids and primers are reported in Appendix A. 
To obtain the triple mutant (BL21 ∆cyoA∆yfbG∆adhP), FRT-PGKgb2-neo-FRT template DNA 
was used as the PCR template. To knock out cyoA, the primer set cyoA F1 and cyoA R1 was 
used to amplify a 1737 base pair (bp) DNA fragment containing a kanamycin cassette. The PCR 
product was purified and stored at −20 °C. Initially, to prepare cells for homologous 
recombination, electrocompetent BL21 cells were mixed with the plasmid pRedET and placed in 
an Eppendorf Electroporator 2510 (Fisher Scientific, Pittsburgh, PA, USA). The transformants 
were selected at 30 °C on Luria-Bertani (LB) agar plates with 3 µg/ml tetracycline. A clone was 
inoculated in 1 mL LB, and incubated at 30 °C until the A660 was about 0.3. Then, it was induced 
with L-arabinose to a final concentration of 0.4% at 37 °C for 1 h. Subsequently the induced 
competent cells were transformed with 2 µL (500 ng) of the prepared linear PCR product. The 
culture was centrifuged and streaked out on LB agar containing 15 µg/mL kanamycin.  
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For analyzing positive colonies by PCR, candidates were picked and resuspended in 30 
µl of distilled water. Samples were boiled at 98 °C for 5 min and employed as templates for the 
PCR reaction. The primers Kan F/cyoA R2 were added to amplify a 451 bp fragment. A positive 
colony carrying the flipase recognition target site (FRT)-flanked kanamycin cassette in place of 
cyoA was transformed with 706-FLP at 30 °C, then incubated at 37 °C overnight. Then cultures 
were incubated on fresh LB agar at 37 °C for 10 h. Colonies were replica-plated on two LB agar 
plates, one containing 15 µg/ml kanamycin, the other one without antibiotic. The clones that 
grew only on LB agar without kanamycin were chosen for PCR identification with the primers 
cyoA F2 and cyoA R2. A 203 bp DNA fragment was visible as the cyoA gene was knocked out. 
This strain was designated BL21 ∆cyoA. The same methodology was used in series to knock out 
yfbG, and adhP respectively, by repeating homologous recombination, identification, and 
removal of kanamycin resistance. Confirmation of mutants was by Southern blotting using 
standard techniques and probes listed in Appendix A. 
For the construction of WHHHPH-GFPuv, plasmid GFPuv was obtained (Clontech, Palo 
Alto, CA). The primers F (5-GCC AAG CTT GTG GCA TCA TCA TCC GCA TAT GAG TAA 
AGG AGA AGA ACT TTT C-3) and R (5-TTG GAA TTC ATT ATT TGT AGA GCT-3) 
contained HindIII and EcoRI sites (underlined correspondingly), were used to polymerase chain 
reaction (PCR) amplify GFPuv. GFPuv was digested and ligated with the same enzyme sites in 
pGFPuv plasmid. BL21 (DE3) was transformed with plasmid WHHHPH-GFPuv. 
Transformation was according to the Promega PureYield plasmid miniprep system (Promega, 
Madison, WI, USA). 
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E. coli DH5α expressing his6-tagged GFPuv was used for IMAC breakthrough 
experiments. The strain was constructed as described in a prior work.105 For subsequent analysis 
of host cell proteins by DIGE and peptide mass fingerprinting, E. coli BL21 (DE3) (Stratagene, 
La Jolla, CA, USA) expressing the same plasmid was utilized. 
2.1.2 Cell growth and medium 
For studies pertaining to knockout of host proteins and the “low-background” elution region of 
IMAC, overnight cultures of BL21 in 25 g/L LB were grown from single colonies on LB agar 
plates containing 50 µg/mL ampicillin and used for inoculating 500 mL cultures in M9 
supplemented with 10 g/L glucose. For strains expressing his6- or WHHHPH-GFP and for all 
succeeding IMAC studies, overnight cultures in 25 g/L LB, supplemented with 50 µg/mL 
ampicillin, were diluted 1:25 in 500 mL fresh LB in a 2-L flask. Cells were induced with 1 mM 
IPTG at 1-2 hrs when A660 was approximately 0.4. Fermentations were carried out in a shaker at 
37°C and 200 rpm for 6-8 h until the A660 indicated strains were in stationary phase. Cell pellets 
were collected by centrifugation at 5000 x g and stored at -80°C prior to lysis. E. coli BL21 
(DE3) without plasmid was also grown as described without antibiotic or induction. 
2.1.3 Sample preparation 
Cell pellets were suspended in 20 mL of the appropriate chromatography starting buffer, then 
supplemented with Triton X-100 to 0.5%, 0.4 mM MgCl2, 1 mM phenylmethylsulphonyl 
fluoride (PMSF) and 0.5 mg/mL lysozyme. Contents were stirred with a glass rod and incubated 
on ice for 10 min prior and during sonication at 7 W (RMS) for 15 min using a Vibra cell 
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ultrasonifier (Thermo Fisher Scientific, Rockford, IL, USA). Cell debris was pelleted at 5000 
rpm for 20 min at 4°C and supernatants were passed through a 0.45 µm filter prior to column 
loading. When more sample volume was required, filtered supernatants from multiple pellets 
were combined. 
2.1.4 Chromatography 
Unless otherwise noted, chromatography steps were carried out with an ÄKTAprime Plus and 1 
mL HisTrap FF columns (GE Healthcare, Piscataway, NJ, USA). Columns were equilibrated 
with 10 column volumes (CV) of dH2O, followed by starting buffer at 1 mL/min. For IMAC 
breakthrough trials, lysate solutions containing 20 or 50 mM imidazole were applied to the 
column until outlet GFP concentration reached a plateau. Subsequent IMAC purifications for the 
purpose of analyzing bound proteins were standardized so sample loading volume and mass were 
equivalent to 10% GFP breakthrough. After sample loading, columns were equilibrated with 
starting buffer until the A280 reached baseline and stripped using an EDTA buffer (50 mM 
NaH2PO4, 0.5 M NaCl, 0.1 M EDTA, pH 8.0). Fractions of 1 CV were collected as needed. 
Columns were equilibrated with dH2O, cleaned by passing through 5 CV of 1 M NaOH, then 
regenerated and stored according to the manufacturer’s specifications. 
2.1.5 Protein concentration, assessment, and SDS-PAGE 
Select fractions were concentrated using Amicon ultrafiltration cartridges with a MWCO of 3 
kDa (Millipore, Bedford, MA, USA). Excessively dilute protein fractions were concentrated by 
trichloroacetic acid/deoxycholate precipitation, dried, and stored at -80°C. Total protein 
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concentrations were determined by the Bio-Rad protein assay using BSA standards (Bio-Rad 
Laboratories, Hercules, CA, USA). Soluble samples were mixed 1:1 with 3X sample buffer, 
incubated in a water bath for 3 min at 75°C. Precipitated samples were resuspended in 3X 
sample buffer and incubated in the water bath at least 6 min for adequate solubilization. Samples 
were loaded into NuPAGE 4-12% Bis-Tris gels and run at 120 V for approximately 1.5 h in 
MOPS running buffer (Invitrogen, Carlsbad, CA, USA). Protein bands were visualized with 
Coomassie G-250 GelCode Blue stain reagent (Thermo Fisher). Gels were scanned at 2400 dpi 
with an Epson Perfection 4490 photo scanner (Long Beach, CA, USA). Densitometry to estimate 
relative protein concentrations and GFPuv purity was performed with ImageJ software 
(http://rsb.info.nih.gov/ij). Image background was subtracted using the “rolling ball” algorithm 
set at 1200 pixels, or half the image resolution, and the sampling box to acquire the density 
profile was approximately one-third the lane width, according to Gassmann et al.106 
2.1.6 Two-dimensional difference gel electrophoresis 
Lysate samples of wild-type strain BL21 (DE3) and those expressing his6-GFP uninduced and 
induced with IPTG were compared. A separate comparison was made with these samples among 
their corresponding proteins that bound during IMAC with 50 mM imidazole loading. Protein 
fractions were desalted using Zeba spin columns (7 kDa MWCO, Thermo Fisher) and 
resuspended in labeling buffer (7 M urea, 2 M thiourea, 4% CHAPS, 25 mM DTT, 30 mM tris, 
pH 8.5). CyDye DIGE fluor minimal dyes (GE Healthcare) were used according to instructions 
to label protein pools. ReadyStrip IPG strips (17 cm, pH range 3-10, nonlinear, Bio-Rad) were 
used for overnight rehydration and isoelectric focusing. After sequential 15 min equilibrations in 
IPG buffers containing DTT and iodoacetamide, the second dimension was run on 17 cm, 10% 
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acrylamide gels in Bio-Rad TGS running buffer (2X in top chamber, 1X in bottom) at 32 mA for 
45 min, 50 mA for 90 min, then 75 mA until the dye front was 2.5 cm from the gel bottom. After 
fixing, gel images were captured using a scientific-grade, cooled CCD imager, custom built by 
Jonathan Minden’s group. Images were imported into Delta2D software (DECODON, 
Greifswald, Germany) for dual-channel image warping and spot fusion, quantitation and 
labeling. Individual samples were reciprocally labeled in six gels, serving as an internal control 
for improved statistical power in spot quantitation. Resolved protein spots have an associated 
average volume, calculated from two independent gels. Average spot volumes with variance 
greater than one standard deviation from the mean were excluded from the quantitative analysis. 
Further detail about the software is available in a previous report.107 
2.1.7 Peptide mass fingerprinting analysis 
Gel spots of interest were manually picked and digested using the methods of Shevchenko et al. 
with a few modifications.108 Briefly, plugs were cut from gel bands and destained. Reduction and 
alkylation utilized 2.5 mM tris(2-carboxyethyl)phosphine (TCEP) and 3.75 mM iodoacetamide, 
respectively, in 100 mM ammonium bicarbonate. Plugs were reduced during incubation for 15 
min at 65°C in an air thermostat and alkylated according to Shevchenko.108 Trypsin Gold 
(Promega) was prepared in 25 mM ammonium bicarbonate. Tryptic peptides (1 µL) were 
deposited on a MALDI plate, dried, and then crystallized with 1 µL α-cyano-4-hydroxycinnamic 
acid (CHCA). Spots were washed by pipetting down then up with 1 µL 0.1% formic acid then 
allowed to dry. MALDI-TOF-MS spectra were acquired with an Applied Biosystems Voyager 
DE Pro (Framingham, MA, USA) with delayed ion extraction and reflection mode. Spectra were 
analyzed using Data Explorer software version 4.6 (Applied Biosystems) by setting the signal-to-
  21 
noise ratio to 5 or higher and filtering the mass list for monoisotopic peaks and charge states of 
one. All identifications were confirmed by searching the SwissProt database (release 2011_02; 
525207 sequences; 185522689 residues) using Mascot search engine (Matrix Science Inc., 
Boston, MA, USA).109 Trypsin was set as the proteolytic enzyme allowing for one missed 
cleavage, oxidation of methionines and carbamidomethyl cysteines selected as variable 
modifications, and peptide mass tolerance set to +/- 0.5 Da or less. 
When needed, simultaneous identification of many spots was done using the same 
general procedure but with equipment capable of high throughput. Gel spots were picked with a 
ProPic II (Digilab, Holliston, MA, USA) following overnight gel staining with SYPRO Ruby 
stain reagent (Molecular Probes, Eugene, OR, USA). Digestion and quadruplicate spotting on a 
384-spot MALDI plate was automated with a Digest Pro MS (Intavis Bioanalytical Instruments 
AG, Cologne, Germany). Mass spectra were acquired with an ABI 4800 MALDI-TOF/TOF 
Analyzer (operation of digestion robot and ABI 4800 were as detailed in a prior report 110). 
2.2 CATABOLITE ACTIVATOR PROTEIN STUDIES 
2.2.1 DNA techniques, strains and plasmids 
The crp gene was amplified by PCR from E. coli BL21 (DE3). Forward primer (5’-GG CAT 
ATG GTG CTT GGC AAA CCG C-3’) was designed to include NdeI restriction site. Reverse 
primer (5’-CC GGATCC TTA ACG AGT GCC GTA AAC-3’) was designed to include BamHI 
restriction site. The PCR product was visualized on a 1% agarose gel, extracted and then cloned 
into electrocompetant E. coli TOP10 from the TOPO TA cloning kit (Invitrogen, Carlsbad, CA, 
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USA) with a Bio-Rad Gene Pulser apparatus. Colonies were grown from which plasmid 
preparations made using the PureYield plasmid miniprep system (Promega). Double digestion 
products were generated with from plasmids with NdeI and BamHI, visualized on agarose gel 
and confirmed by sequencing (Genewiz, South Plainfield, NJ, USA). Preparations of TOPO 
vectors encoding crp and pET21a plasmid (Novagen, Madison, WI, USA) were independently 
digested with NdeI and BamHI. Digestion products were extracted from agarose gels, ligated to 
form pWTcrp, and then transformed into chemically competent DH5α using the calcium 
chloride method. Purified plasmid from DH5α was likewise transformed into BL21 (DE3). 
Site-directed mutagenesis of the crp gene was performed using the QuikChange kit 
according to the manual (Stratagene). Plasmid pWTcrp was used as the template for single 
mutations. Sets of complementary oligonucleotide primers that contained each desired mutation 
were synthesized by Integrated DNA Technologies, Inc. (Coralville, IA, USA). Primers used to 
substitute alanine for His17 were 5’-CG ACT CTC GAA TGG TTC TTG TCT GCC TGC CAC 
ATT CAT AAG TAC CCA TC-3’ and the reverse-complement, generating pH17Acrp (mutated 
bases are indicated in boldface type). Primers used to substitute tyrosine for His19 were 5’-GG 
TTC TTG TCT CAT TGC TAT ATT CAT AAG TAC CCA TCC-3’ and the reverse-
complement, generating pH19Ycrp. To make the double histidine mutation (pH17A-H19Ycrp), 
pH17Acrp was used as a template with the following primer and its reverse-complement: 5’-GG 
TTC TTG TCT GCC TGC TAT ATT CAT AAG TAC CCA TCC-3’. The double mutation 
plasmid was used as a template to create a triple mutant by substituting asparagine for Lys52 
using the following primer and its reverse-complement: 5’-C TCT GTG GCA GTG CTG ATC 
GAT GAC GAA GAG GGT AAA GAA ATG ATC C-3’. All plasmid mutations were 
confirmed by sequencing and independently transformed into E. coli BL21 (DE3). 
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2.2.2 Cell growth and medium 
Overnight cultures of BL21 in 25 g/L LB supplemented with 100 µg/ml ampicillin were diluted 
1:25 in 500 ml fresh LB in a 2-L flask. Cells were induced with 1 mM IPTG at 1-2 hrs when A660 
was approximately 0.4. Fermentations were carried out in a shaker at 37°C and 200 rpm for 6-8 h 
until the A660 indicated strains were in stationary phase. Cell pellets were collected by 
centrifugation at 5000 x g and stored at -80°C prior to lysis. E. coli BL21(DE3) without plasmid 
was also grown as described without antibiotic or induction. 
2.2.3 Sample preparation 
Carried out as described in section 2.1.3. 
2.2.4 Chromatography 
Clarified lysates were prepared in either 20 or 50 mM imidazole buffer and purified using 1 mL 
nickel-immobilized HisTrap FF columns. Twenty CV of lysate was passed over column prior to 
equilibration and elution, either with a single EDTA stripping, or with a linear imidazole gradient 
to 250 mM followed by EDTA. Relevant fractions were collected for analysis. 
2.2.5 Protein concentration, assessment and SDS-PAGE 
Carried out as described in section 2.1.5. 
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2.3 NON-AFFINITY-CHROMATOGRAPHY STUDIES 
2.3.1 Strains and plasmids 
Escherichia coli BL21 (DE3) harboring pGFPuv (Clontech, Palo Alto, CA, USA) was used for 
both HIC and AEX purifications and ammonium sulfate precipitations. BL21 (DE3) expressing 
GFPuv with an N-terminus arg6 tag was used for CEX purification. For cloning arg6-GFP, in 
pGEM3Z as a first step, PCR was carried out using forward and reverse primers and pGFPuv as 
template. Forward primer (5’-ATA AAG CTT CAT GAG TCG TCG TCG TCG TCG TCG 
TAA AGG AGA A-3’) was designed to include HindIII restriction site and six arginine residues. 
Reverse primer (5’-TTG AAT TCA TTA TTT GTA GAG CTC ATC CAT GCC ATG TGT 
AAT CC-3') was designed to include EcoR1 restriction site. The resultant PCR fragment was 
ligated into SmaI restricted pGEM3Z, to produce blunt end ligated arg6-GFP-pGEM3Z. The 
sequence of arg6-GFP-pGEM3Z was confirmed by the DNA sequencing (Molecular Resource 
Laboratory, University of Arkansas for Medical Sciences, Little Rock, AR). The arg6-GFP 
fragment was then subcloned by digesting arg6-GFP-pGEM3Z and pGFPuv with HindIII and 
EcoRI, followed by ligation to produce arg6-pGFPuv. The sequence of arg6-pGFPuv was again 
confirmed and protein expression was verified by Western blotting and fluorescence 
determination. Strains, plasmids and primers used in this study are reported in Appendix A. 
2.3.2 Cell growth and medium 
Fermentations were carried out as stated in section 2.2.2. 
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2.3.3 Sample preparation 
Samples were prepared as described in section 2.1.3 with one exception. Lysate was prepared 
without lysozyme in later experiments that identified host proteins that co-purified with arg6-
GFPuv. 
2.3.4 Purification of non-tagged GFPuv 
All column purifications were performed with an ÄKTAprimePlus purification system with real-
time monitoring of total protein absorbance at 280 nm and pre-packed columns from GE 
Healthcare (Piscataway, NJ, USA) operating at 1 mL/min and room temperature. Operating 
conditions of AEX and HIC purifications were independently optimized using soluble lysate 
from BL21 (DE3) pGFPuv. For AEX optimization, 1 mL HiTrap Q FF columns (GE Healthcare) 
were readied with five CV of start buffer, five CV of high salt elution buffer, then equilibrated 
with start buffer again before loading five CV of soluble extract in varying conditions. Initially, 
optimal pH was determined from a series of experiments where extracts were prepared as 
described above using 20 mM Bis Tris starting buffer containing no salt, then pH adjusted to 
either 5.4, 5.7, 6.0, 6.2, 6.7 or 7.2. After loading, columns were equilibrated with start buffer 
until A280 reached baseline before applying a 20 CV elution gradient from 0 mM to 1 M NaCl, 
followed by five CV of 1 M NaCl before re-equilibration with start buffer. Fractions of one CV 
were collected. Offline, each fraction was assayed for GFPuv fluorescence in triplicate using a 
Tecan Infinite M200 96-well plate reader with excitation/emission spectra set to 395/509 nm 
with subtraction of background fluorescence of non-GFPuv proteins. Extracts were adjusted to 
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pH 6.2 for subsequent runs to optimize the starting ionic strength. AEX runs using start buffers 
containing 50 or 100 mM NaCl were compared in the same manner. 
For HIC optimization, 1 mL HiTrap Phenyl FF low-sub and high-sub columns were 
compared, as were starting ammonium sulfate concentrations. Extracts were initially prepared in 
HIC elution buffer, 20 mM NaH2PO4, pH 7.2. Then 5 mL samples of which were adjusted with 
elution buffers lacking or containing 4 M (NH4)2SO4 to 8 mL, creating a series of extracts in 
starting buffers ranging from 0.7 to 1.5 M (NH4)2SO4 with equal protein concentrations. After 
spin down of any precipitated material and filtration, 5 mL samples were initially applied to the 
low-sub matrix after washing with five CV elution buffer (low salt) and equilibration with start 
buffer (high salt). Sample loading was followed by start buffer equilibration to A280 baseline then 
elution with a 15 CV gradient and five CV equilibration with low salt buffer. Columns were 
regenerated with five CV of distilled water followed by five CV of start buffer. This scheme with 
1.5 M (NH4)2SO4 starting buffer was used to evaluate the high-sub matrix. Fractions of one CV 
were collected and assayed as noted above. 
Final purification for proteomic analysis consisted of initial precipitation, in which 
clarified lysate was adjusted to 1.5 M ammonium sulfate and allowed to incubate on ice for 10 
min prior to centrifugation of precipitated proteins and cell debris (10,000 g, 30 min, 4 °C). 
Supernatant was loaded on low-sub a HIC column and bound proteins were pooled (13 mL), 
sealed in dialysis tubing (MWCO 3500 Da, Thermo Fisher Scientific, Waltham, MA, USA), and 
floated in a graduated cylinder containing 1 L AEX start buffer (20 mM Bis Tris, 50 mM NaCl, 
pH 6.2) with gentle stirring. Buffer was refreshed once after several hours. Five mL of this 
sample was applied to the AEX column using the scheme described above. For comparison, the 
use of buffers, dialysis and order of columns was reversed using the same method. 
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2.3.5 Ammonium sulfate precipitation 
To observe the precipitation behavior of host proteins with respect to varying concentrations of 
ammonium sulfate prior to column application, a soluble extract containing GFPuv was prepared 
as above and eight 1-mL aliquots were placed in 1.5 mL eppendorf tubes. A stock solution of 
saturated ammonium sulfate (541.8 g/L, 25 °C) was prepared and added to each aliquot to create 
a series of concentrations from 0.8-1.5 M in 0.1 M increments. Aliquots were incubated on ice 
for 30 min then spun 30 min at 10,000 g, 4 °C. Supernatants were carefully transferred to new 
tubes without disturbing protein pellets. Stock solution was again added to all aliquots except for 
the 1.5 M tube according to the formula provided by Encore Biotechnology (Gainesville, FL, 
USA, http://www.encorbio.com/protocols/AM-SO4.htm) to achieve final concentrations of 0.9-
1.5 M ammonium sulfate. Solutions were incubated, spun, and separated as before. Pellets were 
washed with 50 µL 20 mM bistros buffer (50 mM NaCl, pH 8.5) before final spin down for 15 
min at 15,000 g, 4 °C. Resulting pellets were resuspended in 3X sample buffer for gel analysis. 
2.3.6 Cation exchange chromatography of arg6-GFPuv 
Operating conditions of CEX purifications were determined using soluble extract from BL21 
(DE3) expressing arg6-GFPuv. Extracts were prepared, in this instance, without the use of 
chicken egg lysozyme (pI 11.35, Sigma, St. Louis, MO, USA) as it interfered with target binding 
in initial trials. Column operation and optimization was similar to that of AEX, using 50 mM 
MES start buffer and extract pHs adjusted to range from 5.5 to 6.0. Five mL of extract was 
applied to HiTrap SP FF columns before start buffer equilibration and NaCl gradient or step 
elations. Ultimate isolation of proteins was carried out at pH 5.7 with a 15 CV gradient from 0 to 
  28 
1 M NaCl. This was immediately followed by a step to 2 M NaCl for ten CV to ensure total 
protein desorption and column regeneration. For comparison, the identical procedure was carried 
out with BL21 (DE3) pGFPuv. 
2.3.7 Protein concentration, assessment and SDS-PAGE 
Carried out as described in section 2.1.5. 
2.3.8 Two-dimensional PAGE 
Concentrated pooled proteins were buffer exchanged with rehydration buffer (7 M urea, 2 M 
thiourea, 4% CHAPS, 25 mM DTT, 30 mM Tris, 0.2% Bio-Rad 3/10 carrier ampholyte, pH 8.5) 
using Zebra spin columns. Protein solution was applied to a 7 cm Bio-Rad IPG strip (pH 3-10, 
nonlinear) in a focusing tray and covered with a layer of mineral oil. Active rehydration was 
programmed for 12 h in the Bio-Rad Protean IEF Cell. Paper wicks were applied to cover the 
tray electrodes before focusing under preset default conditions (with linear voltage ramping and 
a sustained holding voltage at completion to prevent diffusion of focused proteins). Focused 
strips were carefully washed with distilled water then submerged in equilibration buffer (6 M 
urea, 0.375 M Tris-HCl, 2% SDS, 20% glycerol, pH 8.8) with gentle shaking under reducing 
(buffer with 2% DTT) then alkylating (2.5% iodoacetamide) conditions separately for 15 min 
each. NuPAGE Novel 4-12% ZOOM gels (Invitrogen) were used to resolve proteins in the 
second dimension at 120 V for about 1.5 h in MOPS running buffer. Protein spots were 
visualized with Coomassie G-250 GelCode Blue stain reagent. 
  29 
2.3.9 Peptide mass fingerprinting analysis 
Carried out as described in section 2.1.7 without the need for automated, high-throughput 
equipment. 
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3.0  EVALUATION OF ESCHERICHIA COLI PROTEINS WITH AFFINITY FOR 
NICKEL IMMOBILIZED AFFINITY CHROMATOGRAPHY 
3.1 INTRODUCTION 
Immobilized metal affinity chromatography (IMAC) is a primary resolving tool in protein 
biochemistry due in large part to its superb selectivity.14, 104 Target proteins endowed with metal 
binding affinity via polyhistidine peptide tags separate well from proteins in complex, crude 
lysate.16, 20 The relatively few host proteins with functional metal binding sites or clusters of 
surface-exposed histidine residues, however, do co-purify in IMAC and are problematic. Heat-
shock proteins, expressed in reaction to nutrient starvation, oxidative stress, and/or elevated 
recombinant protein production, are among the common contributors to IMAC contamination.103 
After IMAC, removal of these and other co-eluting host proteins from the target protein is often 
problematic due to similarities among the physicochemical properties. Understanding the 
identity of these proteins and the nature of their IMAC binding with respect to target protein 
expression level are critical to formulating a successful strategy that mitigates their removal 
without added purification steps.  
Previous studies within the research group were distinctive for selection and fusion of 
optimum affinity tags to recombinant proteins for improved binding and elution behavior. Beitle 
and Ataai fused an octapeptide derived from angiotensin I with native metal binding affinity to 
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TEM-β-lactamase and successfully purified the fusion in one step with immobilized zinc matrix 
from resolubilized inclusion body material.111 Zinc, instead of the more popular nickel, was 
chosen for the column since its interaction with peptides is more stringent than with almost all 
transition metals used in IMAC; therefore higher purification can be achieved since fewer 
cellular proteins can bind. Aside from conferring zinc binding affinity to the target, this fusion 
peptide had two other advantages over traditional fusion proteins that serve as purification 
handles: (1) it contains only eight amino acids (two of which are histidine), so its minimal size 
imposes almost no metabolic burden on the cell, bypassing the problems experienced when 
recombinant proteins are fused to other full-form proteins and over-expressed; and (2) it is 
derived from the natural peptide angiotensin I, so expression of the target would not be 
confounded by stability, solubility or yield issues sometimes experienced with unnatural handles 
like hexahistidine (his6).112-114 Later, Pasquinelli et al. enhanced this approach with zinc by 
reporting on several affinity tags (notably HPHHGG) that were discovered to direct the elution 
of a recombinant protein to “low-background” regions of the elution profile.105 The recognition 
and exploitation of the “low-background” region, or the specific window of the elution profile 
containing the fewest host protein, is critical to this and similar studies. 
Patwardhan and Ataai detailed the effect of loading pH on binding capacity and target 
purity by mathematically modeling the parameters that govern purification from E. coli extract 
using immobilized copper.33 Predictions of the model were evaluated experimentally to confirm 
that loading extract at an intermediate pH of 6.5 to 6, as opposed to a high pH of 7.25, resulted in 
decreased binding of impurities and higher binding capacities of the target protein (i.e. the “low-
background” region). Next, optimum affinity tags were selected from phage-displayed peptide 
libraries that expressed a diverse array of hexamers as a viral coat protein (this method also 
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generated the peptides identified by Pasquinelli mentioned above). Copper-immobilized beads 
were put in suspension with the phage library at a desired pH and centrifuged, allowing selection 
for hexamers that only remained bound to the beads at a pH relevant to the “low-background” 
region.24 After repeating the experiment with nickel resin,115 24 hexamers were identified as 
having optimal affinity (one of which being WHHHPH for nickel, which is a tag that will be 
addressed in the next section). This technique was later applied by Jiang et al. to identify a 19-
mer peptide with optimal affinity for cobalt matrices that allowed purification of active herpes 
simplex virus type 1 based gene therapy vectors.116 
Described in the next section is the first exploration into host cell design, and how it 
proved successful in demonstrating that comprehensive data of co-purifying proteins could be 
used to enhance the “low-background” elution region by removing unessential genes that express 
contaminating proteins. This recalls the theme mentioned in the opening paragraph of this 
chapter.  
The results presented and discussed in the subsequent sections showed progression of my 
preliminary approach with identification of all IMAC-binding proteins above a specified affinity 
threshold, and thus are relevant to purification of any generically expressed, histidine-tagged 
recombinant protein. I also explored how contaminating protein pools change as recombinant 
protein expression is altered. It was hypothesized that strong-binding contaminants become more 
prevalent relative to the target protein as its expression diminishes. Two-dimensional difference 
gel electrophoresis (DIGE) – invented by Jonathan Minden117 and advantageous for 
circumventing the gel-to-gel variation of two-dimension gel electrophoresis by independent 
labeling of two or three protein samples with fluorescent dyes and resolving them on a single 
gel118, 119 – was employed to monitor such profile changes in the proteome and IMAC-binding 
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pool. This tool supplemented my proteomic-based approach to streamline bioseparation. The 
results led me to put forth a recently conceived strategy that mitigates IMAC contamination by 
essential gene products with protein surface modifications, which is the subject of chapter four. 
3.2 IDENTIFICATION AND KNOCKOUT OF HOST PROTEINS THAT 
CONTAMINATE A STRATEGIC ELUTION REGION IN NICKEL IMAC 
To examine nickel-NTA (nitrilotriacetic acid), the most frequently used IMAC resin, cultures of 
BL21 grown overnight in LB were used to inoculate 500 mL of M9 minimal media 
supplemented with 10 g/L glucose. In a manner described in the methods, pellets were produced 
and resuspended with IMAC start buffer (50 mM NaH2PO4, 500 mM NaCl, pH 8.0) without 
imidazole. Filtered lysate was applied to 4 mL ProBond nickel-chelating resin in an open column 
and after loading and equilibration with start buffer, step elutions were carried out with the same 
buffer at the following imidazole concentrations: 60 mM, 80 mM, 100 mM, 120 mM, and 200 
mM. This was followed by column stripping with 500 mM EDTA. The elution volumes for each 
step were 24 ml, or 6 CV at a flow rate of 0.5 mL/min. 
Figure 3.1 illustrates the protein concentrations in each fraction normalized to the total 
protein used for column loading (note that the scale of normalized protein concentration is 
logarithmic). Containing the lowest amount of host proteins, the fraction at 120 mM imidazole 
was deemed the “low-background” region of the elution profile, so proteins pooled from that 
peak were of keen interest for further study. SDS-PAGE and LC-MS/MS were used to identify 
the cellular proteins present in the “low-background” region (in this instance, mass spectrometry 
was performed independently by the University of Pittsburgh Genomics and Proteomics Core 
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Laboratory). Briefly, three spots were excised from each band and each digested with trypsin. 
Peptides were separated by liquid chromatography (LC) and then identified by tandem mass 
spectrometry (MS/MS) fragmented by collision-induced dissociation. The LC/MS data were 
searched against the MSDB database (20040106, 1319480 sequences) with MASCOT v. 2.1. For 
positive identification, spectral data from each of the three spots matched.  
A total of 18 proteins were identified, presented in Table 3.1. They were classified based 
on their functionality and essentiality to the cell. Genes are essential when strains deficient in the 
gene cannot survive. Strains survive the deletion of non-essential genes, but are not necessarily 
suitable for a biotechnology application. From the identifications, nine genes are non-essential, 
eight are essential, and one is unknown. Functional classification are as follows: eleven are 
associated with DNA binding, RNA binding and protein biosynthesis; five contained metal ion 
binding sites; one involved in carbohydrate metabolism; and one was of unknown function. Four 
of the proteins, DnaK, YfbG, Fur and SlyD, were previously reported as impurities in IMAC 
purification schemes.103, 120 Further inspection of data in Table 3.1 reveals that the four heaviest 
proteins, CyoA, YfbG, AdhP, and DnaK, are all nonessential. To demonstrate the cellular 
engineering approach to improve protein purification, focus was given to the four proteins with 
the larger molecular weights. Mutants lacking dnaK do survive, but have been reported to grow 
poorly.121 Thus, a triple knockout mutant that does not express cyoA, yfbG, and adhP was 
constructed. 
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Figure 3.1. Normalized protein concentration of each fraction during nickel IMAC purification.  
Clarified E. coli lysate was passed through an immobilized nickel column and eluted by step-
gradient increases of imidazole. A “low-background region” was observed in the 120 mM 
elution fraction, in which the smallest amount of host protein eluted from the column relative to 
the loading material, showing here on a logarithmic scale. This region is ideal for directing the 
elution of a theoretical target protein. 
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Table 3.1. Proteins identified to elute in the “low-background” region of nickel IMAC.  
Proteins were identified by LC-MS/MS and their essentiality to the cell is referenced as ‘E’ 
(essential) or ‘N’ (non-essential).  
 





1 dnaK N 638 4.83 68,984 Replicative DNA helicase / nucleotide and protein binding 
2 yfbG N 660 6.39 74,158 
Nucleoside-diphosphate-sugar epimerases / fused 
UDP-L-Ara4N formyltransferase and UDP-GlcA 
C-4'-decarboxylase / surface histidine protein. 
3 adhP N 336 5.94 35,249 alcohol dehydrogenase / Zn-dependent alcohol dehydrogenases / metal ion binding 
4 cyoA N 315 6.76 34,780 Ubiquinol oxidase subunit 2/ Native metal-binding proteins(copper ion binding)  
5 rplB E 273 10.93 29,729 50S ribosomal protein L2 / RNA binding 
6 slyD N 196 4.92 20,722 FKBP-type peptidyl-prolyl cis-trans isomerase SlyD / metal ion binding 
7 nagD N 250 5.18 27,032 UMP phosphatase /N-acetylglucosamine metabolism / carbohydrate metabolism 
8 ahpC N 187 5.03 20,630 alkyl hydroperoxide reductase C22 subunit / ATP-binding 
9 rpsG E 156 10.3 17,473 30S ribosomal protein S7 / RNA binding 
10 rplO E 144 11.18 14,835 50S ribosomal protein L15 / RNA binding 
11 rpsE E 167 10.11 17,472 30S ribosomal protein S5 / RNA binding 
12 rplM E 167 9.68 18,645 50S ribosomal subunit protein L13 / protein biosynthesis 
13 Fur N 148 5.68 16,664 ferric uptake regulator / COG0735: Fe2+/Zn2+ uptake regulation proteins / metal ion binding 
14 -- -- 183 4.68 20,269 Putative uncharacterized protein ECs2542  
15 rplJ E 165 9.04 17,711 50S ribosomal subunit protein L10 / RNA binding 
16 rpsL E 124 11.01 13,765 30S ribosomal protein S12 / RNA binding 
17 Hns N 137 5.44 15,409 
DNA-binding protein H-NS / global DNA-binding 
transcriptional dual regulator H-NS / DNA binding 
and transcription 
18 rplL E 121 4.6 12,164 50S ribosomal protein L7/L12 / protein biosynthesis 
  37 
Knockout strains were prepared using Red/ET homologous recombination and confirmed 
by southern blotting and SDS-PAGE, shown below in Figure 3.2. Probes for the three host 
proteins were used to detect the presence of their DNA sequences in the host genome, forming 
bands when hybridization occurs. The absence of bands indicates successful knockout of the 
sequence, which is shown in the first panel. Lysate from each mutant was subjected to IMAC 
again and their “low-background” regions were compared in the second panel. Observing the 
lanes from left to right, three distinct bands are consecutively removed from the protein pool. 
The gel lane of triple mutant appears significantly clearer than its wild-type parent strain. 
 
 
Figure 3.2. Confirmation of knockout strains.  
(A) Confirmation by Southern blot is apparent when complimentary oligonucleotide probes do 
not interact with their corresponding genes. When the gene is present in the harvested DNA, 
bands appear in the gel. (B) Confirmation by SDS-PAGE. 
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An important feature of an engineered host for protein production is that it be able to 
grow at rates comparable to that of the strain from which it was derived. Additionally, the 
expression of exogenous protein should be comparable. The growth rates and protein expression 
of plasmid-encoded GFP were compared between the triple mutant and parent strains (Figure 
3.3). In M9 minimal media supplemented with 10 g/L glucose, both strains grew at the same rate 
(shown in panel A). Strains were also assayed for GFP expression by specific fluorescence 
intensity, where every sample was diluted to an A660 of 0.1 before measurement. The triple 
knockout mutant displayed better GFP expression than the wild-type strain (panel B). The data 
indicates that removal of the three host proteins was without any ill effects. 	  
 
Figure 3.3. Growth rate and recombinant GFP expression of wild-type and triple mutant strains.  
(A) The time course of growth for the parent (WT) and triple KO strains. (B) The time-
dependent expression of plasmid-encoded GFP, normalized to the corresponding A660 value.  
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To illustrate the feasibility of directing the elution of a target protein to a region of few 
natural contaminants, native GFPuv was selected as a model protein. The GFPuv affinity for 
Ni(II)-NTA is low and thus will require fusion to an affinity tag to direct its elution to 120 mM 
elution window. The elution behavior of native GFPuv and his6-GFPuv were compared. His6 is 
the most often used affinity tag for purification of proteins on immobilized nickel. The affinity 
tag WHHHPH was also compared, which is a tag slightly weaker than his6 that was identified in 
the phage display library experiment previously mentioned. The chromatogram in Figure 3.4 
shows how his6 directed GFPuv to elute in the now enhanced “low-background” region of the 
IMAC elution profile. Figure 3.5 shows WHHHPH-GFPuv breakthrough during loading and 
elution at 80 mM imidazole.  
The results have demonstrated that significant benefits could be gained in downstream 
purification by applying information derived from proteomic-based tools to implement rational 
changes to the host genome without detrimental effects. Here, the strategy was to create a clean, 
discrete elution window in which a recombinant protein could be directed using his6 or other 
tags. The multi-step elution strategy, however, was operationally cumbersome. The next steps 
were to designed to simplify the use of IMAC and to generalize the strategy by identifying all 
IMAC-relevant proteins under conditions that allow a single bind-and-elute step. Further, I 
wanted to observe how the relative host protein concentrations changed as target protein 
expression fluctuated. The remainder of this chapter addresses those issues and proposes an 
unconventional strategy to mitigate target protein contamination. 	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Figure 3.4. Directed elution of GFPuv using a his6 peptide tag.  
Complex lysate with either native (red) or his-tagged GPFuv (blue) were applied to nickel IMAC 
column and eluted by step-wise increases of imidazole. 
 
 
Figure 3.5. Directed elution of GFPuv using a novel affinity tag, WHHHPH.  
Fractions labeled along the x-axis indicates that the WHHHPH conferred GFP elution at 80 mM. 
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3.3 IDENTIFICATION OF NATIVE ESCHERICHIA COLI PROTEINS THAT BIND 
TO IMAC UNDER HIGH IMIDAZOLE CONDITIONS AND USE OF 2D-DIGE TO 
EVALUATE CONTAMINATION POOLS WITH RESPECT TO RECOMBINANT 
PROTEIN EXPRESSION LEVEL 
To assess the effect of increasing the imidazole loading concentration, I compared breakthrough 
curves of E. coli soluble lysates containing his6-GFP in 20 mM and 50 mM imidazole IMAC 
buffers and observed the nickel-binding proteins under each condition (Figure 3.6). For the 
breakthroughs, which illustrate the presence of GFP exiting the column as it reaches capacity 
(Figure 3.6A), exit GFP fluorescence was measured in triplicate and normalized to the input 
fluorescence corresponding to the soluble extract (RFUout/RFUin). Elution volumes for 10% GFP 
breakthrough were 17.2 and 24.6 ml for 50 mM and 20 mM imidazole, respectively. Column 
capacity expectedly diminished with higher imidazole loading. At 10% target breakthrough, total 
column capacity was 38 mg/ml and 85 mg/ml for the 50 mM and 20 mM imidazole runs, 
respectively. GFP yield was 98-99% in both cases. IMAC purifications of each imidazole 
concentration were carried out, with data summarized in Table 3.2 (data sets correspond to 10% 
GFP breakthrough using the curve areas in Figure 3.6A and GFP purity is estimated by 
densitometry from the SDS-PAGE gel Figure 3.6B). 
Table 3.2. Purification table comparing use of 20 mM and 50 mM imidazole in nickel IMAC.  
Purification	  step	   Total	  Protein	  (mg)	   GFP	  (mg)	   GFP	  Yield	  (%)	   GFP	  Purity	  (%)	   Purification	  Fold	  
20	  mM	  imidazole	   	   	   	   	   	  Soluble	  extract	   350	   53	   100	   15	   1	  HisTrap	  FF	   85	   52	   99	   61	   4.1	  
50	  mM	  imidazole	   	   	   	   	   	  Soluble	  extract	   246	   37	   100	   15	   1	  HisTrap	  FF	   38	   36	   98	   95	   6.3	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Figure 3.6. His6-GFP purifications using 20 mM and 50 mM imidazole loading conditions.  
(A) Breakthrough curves of complex lysate containing his6-GFP in loading buffer with either 20 
or 50 mM imidazole. (B) SDS-PAGE gel of comparing the bound protein pools at 10% GFP 
breakthrough. Lanes are: molecular weight ladder (M); 20 mM imidazole load, flow through, 
wash, bound proteins (1-4, repsectively); 50 mM imidazole load, flow through, wash, bound 
protein (6-9, respectively). 
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In the purification runs, columns were loaded with cell extracts in either 20 mM or 50 
mM imidazole to 10% GFP breakthrough, equilibrated and stripped with EDTA. Proteins were 
concentrated, separated by SDS-PAGE, and identified by MALDI-TOF-MS as indicated by gene 
name in Figure 3.6B (Note: extract and flow-through lanes were loaded with 25 µg protein. 
Samples from column wash fractions were excessively dilute, containing approximately 2 µg 
protein in the lane for the 50 mM case. Bound protein lanes were overloaded with 50 µg protein). 
As evident from the gel, elevated imidazole concentration translated to higher nickel binding 
selectivity, noting the estimated GFP purity of 95% using 50 mM imidazole versus 61% for 20 
mM. A minute amount of his6-GFP was also found in the wash fraction at 50 mM. 
For the 20 mM case, several proteins significantly compete with his-tagged proteins; 
among them include bifunctional polymyxin resistance protein (arnA, previously known as 
yfbG), glucosamine-fructose-6-phosphate aminotransferase (glmS), catabolite gene activator 
protein CAP otherwise known as catabolite repressor protein (crp), and 50S ribosomal subunit 
L28 (rpmB). By densitometry, gene products from arnA and glmS accounted for nearly half of 
the non-GFP bound protein mass, whereas they do not bind at 50 mM. In the latter case, while 
small proteins were observed in trace amounts on the gel, only crp was present in amounts that 
allowed identification by MALDI-TOF-MS. 
DIGE was used to observe changes in relative protein concentration in soluble extracts 
and IMAC-relevant proteins as GFP expression level was altered. Here, IMAC with 50 mM 
imidazole loading was used to generate the proteins pools. Comparisons were made among 
strains not transformed with the his6-GFP plasmid, here denoted wild type (WT), and those 
expressing GFP either with or without IPTG induction (induced/uninduced). Table 3.3 illustrates 
the experimental design employed to compare protein groups.  
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Table 3.3. DIGE experimental design comparing soluble lysates and IMAC bound proteins. 
	   Cy3	   Cy5	  
Lysate	  Gels	   	   	  
A	   WT	   Uninduced	  
B	   Uninduced	   Induced	  
C	   Induced	   WT	  
IMAC	  Gels	   	   	  
A	   WT	   Uninduced	  
B	   Uninduced	   Induced	  
C	   Induced	   WT	  
 
 
A brief note is needed on the differential expression of GFP between induced and 
uninduced cases. BL21 (DE3) does not control expression as tightly as other expression vectors 
such as BL21 or BL21 (DE3)pLysS.86 For more direct comparison, it was decided that one strain 
be used to produce all samples. Without induction, GFP was expressed to about 10% soluble 
protein as determined by densitometry of 1D SDS-PAGE gels (not shown).  
Gels were loaded with CyDye-labeled protein pools as indicated in Table 3.3 and spot 
determination and quantitation were resolved with DECODON Delta2D software. Images 
captured for each dye are overlayed so protein spots with differing abundances are illustrated by 
a blue or orange shade accordingly, whereas proteins with similar abundances appear black. Gels 
are shown with associated graphs that correlate these individual protein abundances in each 
sample, giving a quick indication of likeness between protein pools.  
Qualitative and quantitative analyses of the DIGE comparing lysate pools, based on 250-
350 protein spots, revealed that they are considerably similar (Figure 3.7). Expectedly, plasmid-
encoded his6-GFP isoforms and β-lactamase (blaT) stand out in the gels, especially those that 
include the WT pool. In the WT vs. uninduced comparison (Figure 3.7A, where relative 
abundance of spots in WT sample appears orange and uninduced appear blue), GFP and β-
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lactamase were among only 12 resolved spots with average protein volumes that differed by 
more than 1.5-fold. Two spots appear to be cleaved fragments of outer membrane protein A 
(ompA) and another was DNA protection during starvation protein (dps). Other differing spots 
identified were: transcriptional regulatory protein OmpR, NADP-dependent L-serine/L-allo-
threonine dehydrogenase (ydfG), molybdenum cofactor biosynthesis protein B (moaB), and L-
fucose mutarotase (fucU).  
A comparable number of proteins differed in the uninduced (orange) vs. induced (blue) 
DIGE (Figure 3.7B). Among them include UPF0337 protein (yjbJ), galactose-6-phosphate 
isomerase subunit A (lacA) and glutamine-binding periplasmic protein (glnH). Elevated GFP 
expression in the induced sample and the emergence of suspected cleaved or incompletely 
transcribed GFP fragments accounted for other differing spots (marked by unlabeled arrows), 
which are more explicit in the third gel (Figure 3.7C) comparing induced (blue) and WT 
(orange) groups. Phosphoglyceromutase (gpmA) was distinctly over-expressed in the induced 
pool. While the quantitative comparison of spot volume indicates the induced pool is more 
similar to the WT than uninduced, qualitatively that is not apparent from the gel images. This 
finding is likely in part due to the exclusion of reciprocally labeled spots with exceedingly 
variable calculated volumes, resulting in a tighter correlation. In general, results indicating high 
similarity among groups were expected since they were produced in identical culture conditions 
and that DIGE of soluble lysate is primarily a comparison of genome-encoded proteins not 
relevant to recombinant protein production or stress response. 
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Figure 3.7. Two-dimensional fluorescence difference gel electrophoresis of soluble extracts.  
Panels at the right correlate individual spot volumes of corresponding samples, offering a fast 
qualitative comparison. Black gel spots indicate equivalent volumes in the samples. (A) Wild-
type (orange) and Uninduced (blue). (B) Uninduced (orange) and Induced (blue). (C) Wild-type 
(orange) and Induced (blue). 
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The DIGE analysis of IMAC-relevant proteins at varying GFP expression levels is shown 
in Figure 3.8. The gel of WT (orange) and uninduced (blue) pools effectively shows the 
contrasting quantity of IMAC proteins, bound under 50 mM imidazole loading, as expression 
changes (Figure 3.8A). In the WT group are common IMAC contaminants such as crp, host 
factor-I protein (hfq), and ferric uptake regulator (fur). As expected, FKBP-type peptidyl-prolyl 
cis-trans isomerases (PPIases) were present, which in UniProt were attributed to SlyD. While 
these appear to be different PPIases, both spots yielded peptide-level evidence of domains 
homologous with SlyD. All other nickel-binding proteins identified also contain histidine 
clusters: ribosomal small subunit pseudouridine synthase A (rsuA), 3-ketoacyl-CoA thiolase 
(fadA), and universal stress protein G (uspG). One important note, this gel displays black-shaded 
areas of spot overlap that suggest presence of his6-GFP in the WT pool. It is believed these areas 
are a result of signal bleed-through due to slight overlapping of fluorophore spectra as no GFP is 
present in standalone gels of WT protein stained with coomassie (not shown). Further, what 
appear as evident “streaks” above the GFP spots are likely artifactual or free fluorescent label in 
the gel. This is based on the observation that after overnight SYPRO Ruby staining, no protein 
spots were discernable with the ProPic II imager; and further, gel plugs cut from those regions 
did not yield spectra with MALDI-TOF/TOF-MS. 
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Figure 3.8. Two-dimensional fluorescence difference gel electrophoresis of IMAC proteins.  
Panels at the right correlate individual spot volumes of corresponding samples, offering a fast 
qualitative comparison. Black gel spots indicate equivalent volumes in the samples. (A) Wild-
type (orange) and Uninduced (blue). (B) Uninduced and Induced (blue). The evident streaks in 
panel B are due to residual fluorescent dye in the gel and does not represent the presence of 
protein (see text for details). 
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The uninduced pool essentially appears as a two-dimensional, fluorescent-labeled 
representation of Lane 9 in Figure 3.6B as it almost entirely consists of his6-GFP and crp. This 
is more clearly illustrated in Figure 3.8B. The quantitative results from its comparison with the 
induced pool (blue) show virtually no differences in average spot volume. While it is expected 
that these groups be mostly comparable, this degree of equivalence is perhaps artificially high 
due to the mentioned overlapping fluorophore spectra. This idea is based on more distinctly 
varied levels of GFP expression determined by densitometry on SDS-PAGE gels. The DIGE gel 
comparing induced and WT IMAC samples was omitted since it did not noticeably differ from 
Figure 3.8A. Further, one suspected GFP fragment, also present in the GFP-containing lysate 
pools, was confirmed by MALDI-TOF/TOF-MS. A list of all identified proteins is presented in 
Table 3.4. High confidence Mascot scores determined protein identities. Where available, fold 
expression values are given for spots evaluated by DIGE. For clarity, GFP isoforms are omitted 
from the list, though all corresponding labeled gel spots met the minimum significant confidence 
Mascot score. 
The effect that target expression level has on contamination, observable with DIGE, was 
illustrated with another model protein. This work was carried out by collaborators in Arkansas, 
Robert Beitle and colleagues, and is briefly presented here since it neatly corroborates the 
findings just discussed. A recent construct by Hatefi et al. used for gene therapy applications is 
expressed at only microgram levels in E. coli as a result of its composition and biophysical 
properties.122 This construct, a N-terminal extension of fibroblast growth factor 2 (FGF2) 
contains a sequence of lysine and histidine necessary for therapeutic DNA condensation and 
endosomal uptake, and as such, the rather high histidine content of (KKKHHHHKKK)6-FGF2 
permits recovery via metal affinity. The protein fusion was expressed in E. coli BL21 growing 
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aerobically using an exponential fed batch strategy in an Applikon Bioreactor (Foster City, CA, 
USA). Base media was minimal, consisting of 10 g/L glucose, 15 g/L K2HPO4, 7.5 g/L KH2PO4, 
2 g/L citric acid, 2.5 g/L (NH4)2SO4, 2 g/L MgSO4-7H2O and 1 mL of trace element solution per 
liter. Trace elements per liter of 1 M hydrochloric acid were 2.8 g FeSO4-7H2O, 2 g MnCl2-
4H2O, 2.8 g CoCl2-7H2O, 1.5 g CaCl2-2H2O, 0.2 g CuCl2-2H2O and 0.3 g ZnSO4-7H2O. An 
exponential feeding strategy was designed to supplement a solution containing 700 g/L of 
glucose, 20 g/L of MgSO4-7H2O, 1 ml of trace element solution, 5 g/L yeast extract, and 35 ml/L 
of 2x LB. Note also that antifoaming agent and arabinose (inducer) were appropriately added 
during cultivation. This protein fusion itself was further endowed with a C-terminal his6 tag and 
purified by IMAC from complex cell extract, shown in Figure 3.9. Sequence data from mass 
spectroscopy (not shown) confirmed bands corresponding to a FKBP-type PPIase (again denoted 
SlyD) and (KKKHHHHKKK)6-FGF2-his6. As such, both proteins were present in the pool 
fraction represented by Lane 1. Pure SlyD is shown in Lane 2. The results indicated that without 
care, the majority of the elution pool could in fact be comprised of the E. coli protein and not the 
target. 
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Figure 3.9. SDS-PAGE gel comparing a pooled aliquot of IMAC-purified (KKKHHHHKKK)6-
FGF2-his6 and pure SlyD.  
Lanes are: 1, purified protein sample; M, molecular weight ladder (sizes are arbitrary for this 
comparison and are not show); 2, pure SlyD. 
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Table 3.4. List of proteins identified in this study relevant to IMAC. 









Fig. 3.6B arnA Bifunctional polymyxin resistance protein P77398 23 122  
 glmS Glucosamine-fructose-6-phosphate aminotransferase P17169 45 220  
 astC Succinylornithine transaminase P77581 31 98  
 ndh NADH dehydrogenase P00393 16 61  
 rplB 50S ribosomal protein L2 P60422 36 127  
 crp Catabolite gene activator P0ACJ8 32 93  
 ycfP UPF0227 protein P0A8E1 35 69  
 rpmB 50S ribosomal protein L28 P0A7M2 44 62  
 
Fig. 3.7A ompR Transcriptional regulatory protein P0AA16 33 99 2.0* 







 dps DNA protection during starvation protein P0ABT2 72 552 -2.1 
 moaB Molybdenum cofactor biosynthesis protein B P0AEZ9 40 72 -1.8, -1.8* 
 blaT Beta-lactamase TEM P62593 41 220 --- 
 ydfG NADP-dependent 3-hydroxy acid dehydrogenase P39831 29 156 --- 
 fucU L-fucose mutarotase P0AEN8 26 59 --- 
 
B lacA Galactoside O-acetyltransferase P07464 17 76 1.9 
 yjbJ UPF0337 protein P68206 68 77 -1.9, 4.1* 
 glnH Glutamine-binding periplasmic protein P0AEQ3 26 131 --- 
 
  53 
Table 3.4. (continued). 
C gpmA 2,3-bisphosphoglycerate-dependent phosphoglycerate mutase P62707 35 302 --- 
 























 fadA 3-ketoacyl-CoA thiolase P21151 39 391 --- 
 rsuA 16S pseudouridine 516 synthase P0AA43 34 172 --- 
 fur Ferric uptake regulator P0A9A9 32 193 --- 
 uspG Universal stress protein G P39177 52 77 --- 
 
* Denotes fold expression of redundant spot found in Figure 3.2C. 
a  Denotes an acidic isoform or fragment. 
b  Denotes a basic isoform or fragment. 
h  Indicates the relatively heavy Hfq spot. 
s  Indicates the relatively small Hfq spot  
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3.4 DISCUSSION 
The IMAC strategy was simplified to a single bind-and-elute step to capture and identify all 
contaminants with binding retained above a certain imidazole threshold. This eliminates the need 
to consider the precise binding strengths of various his-tagged proteins, e.g. the pH or imidazole 
concentration at which they elute in traditional bind and gradient-elute schemes. Breakthrough 
curves (Figure 3.6A) show that use of 50 mM imidazole lowers the total protein binding 
capacity relative to 20 mM, in this case from about 80 to 38 mg/ml (Table 3.2). However upon 
loading to 10% target breakthrough, his6-GFP binding was only reduced by 30% (52 mg at 20 
mM imidazole versus 36 mg at 50 mM) and consequentially the purity was improved. 
Several of the proteins identified are familiar IMAC contaminants (Fig. 3.6B). SlyD, Fur, 
and ArnA were mentioned in the discussion on the prior IMAC work, in which arnA was 
knocked out without ill effects to cell growth or recombinant protein expression.123 In addition to 
these proteins, host factor-I protein (HFQ), CAP, and GlmS were previously discussed by 
Bolanos-Garcia & Davies.103 Of these contaminants, the most substantial were ArnA and GlmS. 
GlmS catalyzes the synthesis of D-glucosamine-6-phosphate, a precursor of amino sugars N-
acetyl-D-glucosamine and D-glucosamine, which are essential building blocks of the cell 
envelope. Strains deficient in glmS require sufficient exogenous sources of these amino sugars to 
maintain cell viability.124, 125 GlmS monomers contain 24 histidine residues, making it an 
unfavorable candidate for site-directed mutagenesis as well; therefore, use of higher imidazole 
concentration is the best current approach to eliminate its presence in target protein pools. 
  55 
DIGE analyses of the lysate pools primarily attest to their similarity, irrespective of 
recombinant protein concentration. This was in large part due to analysis of only the soluble 
extract of the cell lysate, an approach favored for two reasons. Primarily, my focus was to 
identify IMAC-relevant proteins encountered during purification of a target with ideal, soluble 
expression. I also expected to minimize the capture of some stress-response proteins and 
chaperones such as DnaK/J, ClpB, IbpA/B, GrpE, GroEL/S, and SlyD. Indeed they were largely 
unseen in the DIGE, whereas with an approach that includes analysis of insoluble protein bodies, 
I would have expected higher presence of these proteins and differing expression with respect to 
IPTG induction.91 Plasmid-encoded proteins aside, the proteins that differed most across the 
samples have widely varying functions and appear unrelated. 
One point to note is the prominence of SlyD at low recombinant protein expression 
(Figure 3.8A). Certainly SlyD is a troublesome contaminant when steps are taken to resolubilize 
inclusion bodies to purify aggregated recombinant protein. Additionally, its presence in IMAC 
purified fractions increases as his-tagged protein expression is lessened due to competition for 
column binding sites. This was clearly observed upon examining the recovered pools of purified 
(KKKHHHHKKK)6-FGF2-his6, where SlyD and the target are difficult to resolve (Figure 
3.9). The key issue raised in this contribution by Beitle and colleagues is that under such 
circumstances, owing to the close molecular weight of this example, SlyD could be mistaken for 
the true target product because of reactivity with anti-his tag antibodies used in Western blot 
analysis. Similar issues could be encountered with other desired recombinant proteins of similar 
molecular weight tagged with enhanced histidine content, viz. when SlyD displays similar elution 
and migration behavior, the possibility of providing false specific activity values exist because 
the prominent band is thought to be the true material both due to biological activity (assay) and 
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cross reactivity (Western). Therefore, the absence of spectroscopy data combined with both 
direct observation of the gel (the figure is an enlarged photograph of a small format gel) and 
nonspecific anti-his Western data would tempt one to identify the faster migrating band as the 
target. For the case of (KKKHHHHKKK)6-FGF2-his6 this incorrect migration would be 
rationalized based on the significant charge localization of sixty combined histidine and lysine 
residues, with purity and activity determination severely compromised. 
In the GFP-containing pools where target protein expression levels were at least 10% 
soluble protein, however, many common IMAC contaminants are not relevant with 50 mM 
imidazole loading. CAP (the gene product of crp) is the only co-purifying protein in this IMAC 
scheme that could be confirmed by MALDI-TOF/TOF-MS. Once again, CAP is known to 
interact with immobilized nickel matrices, but this case has shown it to be the most tenaciously 
bound host protein.  
This finding lends to the hypothesis that with all other things being equal (an ideal rarely 
if ever experienced in cell biology work), a host lacking CAP would allow IMAC purification of 
a sufficiently expressed recombinant target to homogeneity and would thus be strikingly 
advantageous for such an application. Understanding CAP’s cellular role, a transcription 
activator that upon binding with cyclic AMP interacts with RNA polymerase and the promoter 
regions of over 100 genes, it comes as no surprise that mutants lacking CAP exhibit slow growth 
and greater sensitivity to stress conditions.126, 127 It is hypothesized, however, that its nickel-
binding affinity is due to only three histidine residues located in close proximity near the N-
terminus at positions 17, 19 and 21. This convenience provided the fortuitous opportunity to test 
both stated hypotheses. And that is why CAP and the nature of its binding to familiar partners 
and IMAC columns is the subject of the following chapter. 
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4.0  RATIONAL MUTAGENESIS OF CATABOLITE GENE ACTIVATOR PROTEIN 
MITIGATES IMAC CONTAMINATION WHILE PRESERVING ITS CELLULAR 
FUNCTION 
4.1 INTRODUCTION 
As a facultative anaerobe, E. coli is capable of surviving on a wide variety of substrates with or 
without the presence of oxygen. It preferentially utilizes one carbon source until depletion before 
utilizing the next, doing so by repressing expression at other catabolic operons in a mechanism 
known as catabolite repression. In absence of the preferred carbon source glucose, high 
cytoplasmic levels of cyclic AMP (cAMP) promote allosteric binding to CAP, which regulates 
transcription at over 100 CAP-dependent promoters. The protein is a 47-kDa homodimer that 
binds to specific DNA regions, enhancing RNA polymerase (RNAP) binding and transcription. It 
was the first transcription activator to be isolated,128, 129 to have its three-dimensional structure 
determined,130 and has since been the focus of thorough biochemical, biophysical, genetic 
research as described in previous reviews.131-133 It is known from my previous studies that CAP 
tenaciously binds to IMAC resins, and given its integral cellular function, it is an unsuitable 
candidate for genomic knockout. Indeed, ∆crp exhibits significantly slower growth126 and greater 
sensitivity to stress conditions such as recombinant protein production.127 To uncover an 
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alternative method to mitigate its IMAC contamination, we must first gain a deeper 
understanding of CAP at each distinct level of protein structure.  
Upon allosteric binding of camp, CAP undergoes a conformational change and forms a 
complex with DNA at a specific region near CAP-dependent promoters. The crystallographic 
structure of the CAP-DNA complex determined by Schultz et al. is shown in Figure 4.1 (protein 
databank entry 1cgp modified with space-filled binding determinants as presented by Busby and 
Ebright). 131, 134 The C-terminal domain of each CAP subunit contains a helix-turn-helix DNA 
binding motif that interacts with the major groove, bending the DNA (represented in red as a 
wire-surface) by about 90°. Histidine residues at positions 17, 19 and 21 are shown as light blue 
space-filled residues in Figure 4.1A. Their close proximity is likely related to their role in IMAC 
contamination. 
At class I CAP-dependent promoters such as lac, transcription activation requires direct 
protein-protein interaction with the C-terminal domain (CTD) of the RNAP α subunit via 
residues 156-164 of the downstream CAP subunit known as “activating region 1” (AR1; multi-
colored space-filled region in Figure 4.1A and indicated in the cartoon of Class I promoter 
interaction in Figure 4.1B).135, 136 This interaction tethers RNAP to the DNA, allowing 
subsequent recognition of promoter elements by RNAP σ70 subunit and catalytic activity by β 
and βʹ′ subunits. Substitution of any residue within AR1, particularly Thr158, will reduce or 
eliminate activation without affecting CAP-DNA binding.137, 138  
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Figure 4.1. The CAP-DNA complex at Class I promoters.  
(A) Crystallographic structure of the CAP-DNA complex, modified from Schultz et al. to 
highlight residues that interact with RNAP at Class I promoters. (B) Illustration of CAP 
interaction with RNAP at Class I promoters. 
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At class II CAP-dependent promoters like galP1, however, the DNA site for CAP and 
RNAP overlap (Figure 4.2, featuring protein databank entry 1cgp).134, 139 This requires that AR1 
of the upstream stream subunit of CAP interact with the CTD of αRNAP (Figure 4.2B).140 In 
addition, CAP residues His19, His21, Glu96 and Lys101 of the downstream subunit interact with 
the NTD of αRNAP. These residues make up “activating region 2” (AR2) and are required for 
class II promoter activation. AR2 is not required for RNAP-DNA binding, but rather to increase 
the rate of RNAP-promoter isomerization of closed complex to open.131 Mutational studies 
indicate that the most important structural feature of AR2 is a net-positive charge, which is 
sensible since the interacting residues of α-NTD (162-165) are negative.141 Those studies also 
showed that alanine substitution at His17 (H17A) did not inhibit class II promoter activation and 
tyrosine substitution at His19 (H19Y) retained 40% activation, indicating that they could be 
opportune targets for substitution.141 
Substitution of Lys52 by a neutral or negatively charged residue presents a third, non-
native CAP-RNAP interaction and was found to substantially increase transcription activation at 
class II promoters but not at class I.135, 142 Mutation of Lys52 to asparagine (K52N) strengthens 
CAP interaction with RNAP by 5-fold with respect to the wild-type.141 Alanine substitution of 
nearby residues revealed that Glu58 plays a role in this region, dubbed “activating region 3” 
(AR3).142 These two residues are visible in Figure 4.2A in the downstream CAP subunit. Their 
close proximity suggests that they form a salt bridge that neutralizes their opposing charges. 
Upon substitution of Lys52 to a neutrally charged residue, however, the resulting net negative 
charge in AR3 forms an energetically favorable interaction with the net positive residues 590-
600 of RNAP σ70.143, 144 Their proximity is evident in Figure 4.2B. It is therefore believed that 
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an asparagine substitution at Lys52 would recover lost transcription activation at class II 
promoters that results from other substitutions, e.g. a tyrosine substitution at His19.131 
 
 
Figure 4.2. The CAP-DNA complex at Class II promoters.  
(A) Crystallographic structure of the CAP-DNA complex, modified from Schultz et al. to 
highlight residues that interact with RNAP at Class II promoters. (B) Illustration of CAP 
interaction with RNAP at Class II promoters. 
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Based on the structure and mutation analysis studies and the current understanding of the 
interactions among CAP and its partners, I postulate that a modified CAP protein (H17A, H19Y, 
K52N) would have negligible nickel binding affinity and maintain adequate interaction with 
RNAP. The work presented in this chapter demonstrates that these proposed mutations to CAP 
indeed eliminate its IMAC binding under the conditions presented in the previous chapter. 
Implications from the results are discussed in the context of creating an improved host strain for 
generic recombinant protein expression and purification. 
4.2 RESULTS AND DISCUSSION 
To study amino acid substitutions in CAP and their influence on nickel-binding, the 
chromosomal crp gene was encoded on a pET21 plasmid, downstream of a T7 promoter and 
without use of the optional C-terminal his6 tag, and expressed in BL21 (DE3). Plasmid 
expression of CAP was necessary not only to achieve high inducible cytosolic concentrations 
that allows easier characterization on columns, but also to serve as a template for generating 
mutants of CAP. While gene manipulation could be done with relative ease, intrinsic expression 
of the chromosomal CAP brought some complication since two variants of CAP were expressed 
in all mutant strains. This limitation could have been overcome with chromosomal knockout of 
crp, but given our familiarity with its IMAC binding it was thought satisfactory to compare the 
relative concentrations of bound CAP under identical conditions. 
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The first consideration was the choice of binding conditions. In the previous chapter, 
elevated imidazole concentration during loading was effective in preventing host protein binding 
except for CAP. But such stringent conditions are here not ideal to assess the binding of CAP or 
its altered forms. With a lower imidazole threshold, less material is needed to yield a 
representative pool of bound proteins, wild-type CAP included. 
The gel in Figure 4.3 displays the IMAC purification steps of wtCAP loaded with 20 
mM imidazole (note that lanes correspond with loading material, insoluble pellet, flow-through, 
wash, and elution fractions). What is apparent is the lack of target protein found in the flow-
through fraction and its heavy presence in the subsequent wash and elution fractions. It was 
found to be 78% pure from simply loading at 20 mM imidazole and stripping without the need 
for an affinity tail. This finding is a validation of wild-type CAP’s proclivity to bind with nickel. 
 
 
Figure 4.3. IMAC purification of wild-type CAP.  
Lanes correspond to the complex lysate (Load), insoluble pellet (IP), flow through (FT), wash 
(W) and elution (E) fractions. 
CAP 
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Figure 4.4A shows a gel produced in an identical manner, but from strain expression 
pH17Acrp. Three details support the notion that alanine substitution of His17 results in 
diminished IMAC binding. First, a noticeable band corresponding to the mutant CAP now 
appears in the flow-through lane where it had not with the wild-type case, indicative of CAP 
breakthrough during loading. Given that the amount of CAP in the loading was identical in each 
case, CAP breakthrough is symptomatic of reduced affinity for nickel. This is akin to the 
breakthrough curves of his6-GFP in buffers of different loading imidazole concentrations shown 
in the previous chapter (Figure 3.6A). Second, the mutant CAP more readily washes from the 
column, as the corresponding band was shown by densitometry to be twice as intense relative to 
the wild-type gel. Third, host proteins in the elution fraction have a higher relative concentration, 
as CAP was purified to just 47%. These findings agree with the near identical gel in Figure 4.4B 
that was produced from strain expression pH19Ycrp. While this evidence shows that a single 
histidine substitution in CAP reduces its affinity to nickel, the amount of mutant CAP that 
ultimately remains bound through equilibration and elutes with other host proteins remains 
unclear. 
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Figure 4.4. IMAC purifications of (A) H17A and (B) H19Y mutant CAP.  
Lanes correspond to the complex lysate (Load), insoluble pellet (IP), flow through (FT), wash 
(W) and elution (E) fractions. 
 
Substitution of two histidine residues resulted in greater nickel affinity loss (Figure 4.5). 
The amount of CAP in the flow-through is identical relative to the load material, unlike what is 
found with prior cases. Its presence is also limited in the wash fraction, which is either the result 
of residual load material passing over the column or desorption of bound CAP. The best 
indicator, however, is in the elution fraction, of which CAP only comprises 6%. The relative 
concentrations of other proteins are equivalently higher. The significantly higher amount of 
precipitated CAP in the “IP” lane should be addressed. Substitution of two solvent-exposed 
histidines with polar residues has evidently promoted hydrophobic interactions among CAP 
dimers, resulting in unwanted aggregation and precipitation. This would be cause for concern if 
my aim were to express plasmid-encoded CAP or mutants to high concentrations, where such 
protein interactions are more likely to occur. However, this expression system only serves the 
CAP 
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purpose of evaluating column binding. A host cell with basal chromosomal CAP expression 
would be much less prone to this precipitation; therefore, this issue is not concerning. 
 
 
Figure 4.5. IMAC purification of double mutant CAP (H17A, H19Y).  
Lanes correspond to the complex lysate (Load), insoluble pellet (IP), flow through (FT), wash 
(W) and elution (E) fractions. 
CAP 
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Figure 4.6A is a gel produced in an identical manner from strain expression the triple 
mutant CAP (H17A, H19Y, K52N), which has both histidine substitutions and arginine in place 
of Lys52. Again there is a strong presence of mutant CAP in the flow-through and wash lanes 
and very little in the elution fraction, of which the mutant again comprised just 6%. Figure 4.6B 
was produced from BL21 (DE3) lysate without expression of plasmid. This is a suitable 
comparison since only chromosomal CAP is expressed. In this case CAP comprised 8% of the 
elution pool, which is essentially an identical amount given the error inherent to the gel 
procedure and densitometry analysis. This evidence strongly suggests that the double histidine 
substitution eliminates CAP binding even at 20 mM imidazole. Another approach was used to 
help confirm this finding that only chromosomally expressed CAP is found in the elution fraction 
of the triple mutant case. 
 
 
Figure 4.6. IMAC purification of (A) triple mutant CAP and (B) BL21 lysate without plasmid.  
Lanes correspond to the complex lysate (Load), insoluble pellet (IP), flow through (FT), wash 
(W) and elution (E) fractions. 
CAP 
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It is a safe argument that the wild-type and triple mutant CAP proteins would have 
different affinities for nickel. So if indeed both forms bound to the IMAC resin, they would elute 
in separate peaks during a gradient elution of imidazole. If only chromosomal CAP is present, it 
would elute in a single peak. This is exactly what was found in Figures 4.7 and 4.8. The total 
protein curve of the chromatogram reveals that protein was eluted in a single peak (note that the 
baseline increases in a linear fashion due to the imidazole gradient). The gel shows the wash 
fraction and elution fractions as the imidazole concentration is linearly increased from 20 to 250 
mM. Fractions E1-E6 each represent 1 mL, E7 represent the next 3 mL, E8 the next 3 mL, E9 a 
7-mL equilibration at 250 mM and E10 the EDTA pool. No protein was detected in the latter 
two. The intensity of the CAP band increases from left to right, peaking in the E4 lane, then 
diminishes until it is no longer detected in E8. It should be further noted that elution of CAP in a 
single peak supports the explanation of CAP prominence in the wash fraction, that it is from 
residual lysate passing through the column during column equilibration and not from desorption 
of weakly bound protein. 
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Figure 4.7. Imidazole gradient elution of triple mutant CAP.  
Total protein (blue line) indicates a single elution peak followed the gradient imidazole elution 
(green line). Conductivity is shown in red. 
Single elution peak 
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Figure 4.8. Wash and elution fractions of triple mutant CAP purified by imidazole gradient.  
Each lane indicates a fraction of the gradient elution shown in Figure. 4.7. Lanes correspond to 
wash (W), the first 6, 1-mL elution fractions (E1-E6), pools of the following 3 mL of the elution 
fractions (E7 and E8), a pool of a 7-mL equilibration using 250 mL imidazole (E9), and the 
EDTA fraction (E10). 
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For a final observation, bound proteins of the triple mutant CAP and wild-type strains 
were captured after purification using 50 mM imidazole and resolved by 2D-PAGE, similar to 
the DIGE analysis of the previous chapter except now with Coomassie staining (Figure 4.9). 
Immediately evident is the comparable amount of CAP in each pool (protein spot labeled with an 
arrow), indicating that only chromosomal CAP was captured from the triple mutant. SlyD, a 
familiar IMAC contaminant featured in the previous chapter, is found in both pools. Inducible 
expression of the plasmid-encoded protein resulted in noticeably higher expression of 
chaperonins DnaK, GroEL and ribosomal subunit protein RS1 (the protein cluster in panel A at 
pI 4.9, 57-69 kDa). Elongation factor Tu (43 kDa, pI 5.3), a protein that guides aminoacyl-tRNA 
into the free site of the ribosome, was also captured by IMAC and is seemingly expressed higher 
in the plasmid-containing strain. 
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Figure 4.9. 2D-PAGE of IMAC proteins from (A) triple CAP mutant strain and (B) BL21 (DE3) 
loaded with 50 mM imidazole.  
IEF strips were loaded with equal amounts of protein (50 mg) and the 2nd dimension was run in 
identical conditions. The protein spot corresponding to CAP is marked with an arrow whereas 
the protein cluster referenced in the text is marked with an asterisk. 
* 
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One conclusion from the IMAC studies in the previous chapter validated what others 
have affirmed: that CAP, a protein with low histidine content relative to the other contaminants 
and no metal binding sites, is among the most tenaciously binding host proteins in E. coli, 
capable of contaminating purifications of highly-expressed, his6-tagged proteins even in stringent 
loading conditions.103 Closer examination of CAP, however, provides a likely explanation for its 
affinity for immobilized nickel. Three surface-exposed histidines with two residues spaced 
between can coordinate well with metals. When nickel is immobilized with nitrilotriacetic acid 
as they are in HisTrap columns, only two coordination sites are available for protein binding. 
Thus, substitution of two histidine residues (leaving only a single histidine to interact with 
nickel) was predicted to sufficiently disrupt its affinity to nickel. The results in this chapter have 
given that confirmation and further study should only be done in the context of a host cell 
chromosomally-expressing this modified CAP during plasmid-encoded recombinant expression. 
Thus, this work closes a chapter of research dedicated to optimizing perhaps the most widely 
applied affinity chromatography technique in bioscience. 
 
There is, however, a trend in the biotechnology industry that seeks cost-efficient 
alternatives to affinity methods. In the introductory chapter, two other widely used 
chromatography techniques were discussed, hydrophobic interaction and ion exchange, based on 
hydrophobic and electrostatic interactions. Application of our upstream-downstream integration 
approach for these resins would be quite ambitious indeed, given that all proteins have at least a 
degree of hydrophobicity or net charge (dependent on pH of course). Nevertheless, this is 
precisely the topic of the following chapter. 
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5.0  EVALUATION OF ESCHERICHIA COLI PROTEINS THAT BURDEN NON-
AFFINITY-BASED CHROMATOGRAPHY 
5.1 INTRODUCTION 
As we have seen, affinity chromatography media is favored for its superb selectivity. Media with 
conjugated proteins for monoclonal antibody capture, such as protein A for example, are among 
the most selective. The remarkable performance comes at a cost, however, as protein A resin is 
over 30 times more expensive than typical ion exchange resins.43 Although resin lifetime is 
limited by fouling by product or contaminant build-up, loss is primarily due to ligand 
degradation after repeated cycles of stripping and regeneration.145 To mitigate costs, the number 
of investigations that seek to find alternatives to packed-bed chromatography is trending upward. 
For example, advanced techniques for bulk separation via aqueous two-phase partitioning, three-
phase partitioning, specific and non-specific precipitation, crystallization as well as use of 
uncharged, charged and affinity-based membranes for filtration and chromatography are of high 
interest to industry (see reviews5, 68, 146). Follman and Fahrner characterized seven multi-step 
chromatography schemes using non-affinity based media, particularly hydrophobic interaction 
(HIC), anion (AEX) and cation exchange chromatography (CEX), to assess their performance 
against their customary protein A affinity-CEX-AEX scheme in the purification of Chinese 
Hamster Ovary-derived monoclonal antibodies.43 Three such processes were found to be 
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comparably effective in removing CHO proteins as the more traditional protein A-CEX-AEX 
process. Effective purification of proteins endowed with positively charged polyarginine tails 
have also been demonstrated. Sassenfeld and Brewer pioneered the concept by fusing five 
consecutive arginines to the C-terminus of recombinant human urogastrone.49 Variants of a 
positively charged 58-amino acid sequence excised from the B domain of staphylococcal protein 
A has been successfully used as a fusion tag for protein isolation via CEX.58, 147 Separation to 
high purity of cyclodextrin glycosyltransferase fused to polylysine or polyarginine has also been 
reported.54 
Use of non-affinity based matrices is favored for their low cost and robustness towards 
harsh cleaning procedures, but less selectivity means multiple steps are typically needed to 
remove host contaminants. The solution to this problem can be found in a return to the central 
theme of this body of work: improved efficiency in the downstream phase can be gained by 
integrating rational host design upstream. We know from prior discussion that this requires 
focused examination of host proteins that remain bound to column matrix after equilibration, 
which reduces capacity for the target protein, as well as proteins that co-elute with the target 
itself. These proteins are particularly bothersome since they reduce final purity and resolving 
such proteins (with similar physicochemical properties to the target) complicate the process with 
additional, orthogonal purification steps that drive up operational costs and detriment overall 
yield.  
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Evaluation of such troublesome proteins is the basis of the work presented in this chapter. 
I now apply our familiar techniques to improve knowledge of host proteins with a likelihood of 
contaminating two schemes base on hydrophobic and electrostatic interaction, HIC-AEX and 
polyarginine-aided CEX. Based on the results, preliminary direction for development of tailored 
host strains with intrinsically improved separation performance is discussed. 
5.2 PURIFICATION OF NON-TAGGED GFP 
Before describing how the host proteins were captured, a general comment is needed on my 
general purification strategy and the choice to use GFPuv as a model protein. GFPuv was a well-
suited choice for a generic model protein not only for convenient assay, but its medium size (27 
kDa) and acidic isoelectric point (pI 5.7) are reasonably average in the context of the host 
proteome. For instance, the distribution of E. coli proteins by pI is bimodal and the mean pI of 
the acidic protein group is about 5.5-5.7 (the mean pI of the basic protein group is about 9.5); 
while the average size of a typical E. coli is 35 kDa.148, 149 Ideally, a group of model proteins 
with a spectrum of sizes and net charges would be used. The resulting analysis would perhaps 
generate a more complete list of host proteins that contaminate the IEX step across a broader 
range of binding parameters. This could allow design of a host strain with intrinsically better 
downstream efficiency that is more robust to IEX conditions. In light of this idea, process 
development that established only the most fundamental conditions for GFPuv purification via 
HIC and AEX was carried out. I chose this approach so these processes, with minimal alteration, 
could be applicable for purification of a wider range of target proteins. Further, by not fully 
optimizing the binding and elution conditions for GFPuv, the intent was to put less restriction on 
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the likelihood that any identified contaminants could appear in similar processes in which a 
protein of interest is purified. Ultimately, however, the overall approach can be applied to cases 
where a target requires binding or elution conditions that significantly deviate from those 
reported here. Contaminants relevant to that specific process could then be identified. 
5.2.1 Optimization trials on HIC and AEX columns 
The variables pertaining to HIC were first explored. The effect of pH on target retention in HIC 
is complicated. While it can be said generally that increasing pH weakens hydrophobic 
interactions and decreasing pH increases them, pH is specifically a modulator of amino acid 
ionization. Its effect on retention is thus amplified if the ionization states of the residues at the 
site of interaction with the support matrix can be altered. This suggests that both hydrophilicity 
and hydrophobicity moderate retention. Further, variation in target retention is considerably 
dampened in the range pH 5-8.5.150 Given these considerations and noting again that purification 
of GFPuv is not the specific intention, pH was not varied in the loading or elution buffers.  
Columns of 1 mL HiTrap Phenyl FF that contain phenyl groups at low density (low-
substitution) and high density (high-substitution) were compared, as were starting ammonium 
sulfate concentrations. Extracts were initially prepared in HIC elution buffer, 20 mM NaH2PO4, 
pH 7.2. Five ml samples were adjusted with elution buffers either with or without 4 M 
(NH4)2SO4 to 8 ml total volume, creating a series of extracts in starting buffers ranging from 0.7 
to 1.5 M (NH4)2SO4 with equal protein concentrations. Incubation on ice preceded centrifugation 
of any precipitated material. A final filtration resulted in five ml samples which were applied to 
the low-sub matrix. Sample loading was followed by start buffer equilibration until protein 
desorption completed. Elution used a 20 CV gradient and a final five CV equilibration with low 
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salt buffer to remove any residual protein. Fractions of one CV were collected and assayed in 
routine fashion. Columns were regenerated with five CV of distilled water followed by five CV 
of start buffer.  
With samples containing less than or equal to 1 M ammonium sulfate, GFP was not 
retained. For the 1 M trial, the target was visibly present in the flow through and equilibration 
fractions. Trials of 1.2 M and 1.5 M ammonium sulfate gave GFP breakthrough at completion of 
loading of 31% and 6%, respectively, when normalized to the lysate fluorescence. Thus, this 
series of column runs determined that 1.5 M was the lowest ammonium sulfate concentration 
that allowed the desired target retention. Since 6% breakthrough is lower than commonly 
referenced “threshold” of allowable protein loss of around 10%, and higher ammonium sulfate 
concentrations would only increase the likelihood of excessive precipitation, further tuning of the 
salt concentration was deemed unnecessary. Chromatograms of these trials are shown in Figures 
5.1 and 5.2. (Note that lines representing total protein concentration and conductivity correspond 
to vertical axes. The data series in green represents relative GFP fluorescence with markers 
corresponding to GFP assays of each fraction, whereas the connecting line is purely for display 
purposes. Further, the GFP curves do not correspond to a given vertical axes, but are merely 
scaled and superimposed on the charts). 
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Figure 5.1. Chromatogram of HIC loaded with 1.2 M ammonium sulfate.  
GFP assays (green points with connecting line) indicate that GFP had 31% breakthrough at the 




Figure 5.2. Chromatogram of HIC loaded with 1.5 M ammonium sulfate.  
GFP assays (green points with connecting line) indicate that GFP had 6% breakthrough at the 
end of loading. 
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Starting buffer adjusted to 1.5 M ammonium sulfate was also used to evaluate the high-
sub matrix. The chromatogram in Figure 5.3 shows a significantly wider elution peak relative to 
the low-sub column (the sharp second peak contains trace hydrophobic proteins that only elute 
during wash with pure distilled water post elution). GFPuv was visually detectable in the 
fractions that corresponded with the total protein peak. The apparent decrease in resolution, and 
thus the more cumbersome buffer exchange step for ensuing column steps, lead to the decision to 
focus exclusively on low-substitution matrix. 
 
 
Figure 5.3. Chromatogram of HIC on phenyl high-substitution matrix.  
Total protein (blue line) indicates a wide GFP elution peak relative to the low-substitution matrix 
and residual bound protein after all salt (red line) was washed from the column. 
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A series of AEX trials was performed to determine the optimum operating pH and 
loading salt concentration. Varying the pH is the primary way to influence selectivity in IEX 
applications, that is to say, the order of elution and resolution of peaks. As is commonly done, a 
series of starting buffers with varying pH and no salt are initially used for bind-and-elute 
purifications. After model protein retention is determined in each condition, the optimum pH is 
selected. A new series of buffers, each at the chosen pH, contain varying amounts of NaCl before 
the optimization process is repeated. Since this generalized methodology is more reflective of an 
IEX used as a capture step, as opposed to a polishing step requiring fine-tuning of these and 
other conditions for highest selectivity, it was the favored strategy. One alternative to this would 
have been to skip optimization of the pH entirely, opting to load at say pH 8.0 to promote 
relatively more host protein binding and relatively less of GFP, for example. While this may cast 
a wider net in the exploration of co-purifying host proteins, even a modest attempt to purify any 
target from complex material by IEX would require tuning of the pH in a practical setting. 
Further, I anticipated that proteins of relative abundance in any stage of the purification process, 
not just in the GFP elution fraction, would be scrutinized and perhaps identified from SDS-
PAGE gels. This indeed was the case and will be discussed in the next section of results. 
To briefly summarize the methods, E. coli BL21 (DE3) pGFPuv pellets were resuspended 
in AEX start buffers, consisting of 20 mM Bis Tris at pH 5.4, 5.7, 6.0, 6.2, 6.7 and 7.2. Columns 
were loaded with five CV of lysate and eluted with a NaCl gradient (0-1 M) over 20 CV. Noting 
that the pI of GFP is 5.7, and from prior reports concluding that an optimal pH should be at least 
0.3 units more basic,151 it was hypothesized that pH 6.0 or 6.2 would be optimal. Indeed, curves 
generated under such conditions show unfavorable binding or elution characteristics. Trials at pH 
5.4 and 7.2 showed excessive GFP breakthrough, indicative of a net positive charge in the former 
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and diminished binding capacity due to host protein competition in the latter. Trials between pH 
5.7 and 6.7 yielded similar results, though GFP retention was slightly improved at pH 6.0 and 
6.2. Operation at pH 5.7 would likely prevent addition of little or any salt in the loading, as the 
target would surely wash out given its pI of 5.7. Binding at pH 6.7 was satisfactory but was 
inferior to the pH 6.0 and 6.2 conditions. The convention of a capture step is that the minimal pH 
that removes the most host protein is optimal. 
Trials at pH 6.0 and 6.2 were more carefully examined with SDS-PAGE shown in Figure 
5.4 (Lanes are labeled within the figure and were loaded with 25 µg protein. Note that “Peak” 
refers to the single fraction containing the highest relative amount of GFP, whereas “Pooled” 
refers to a sample mixed from every elution fraction that contained GFP). 
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Figure 5.4. SDS-PAGE comparing AEX runs at pH 6.0 and 6.2.  
The first lane is the molecular weight ladder. Other lanes correspond to the load material, flow 
through, single 1-ml fraction containing highest amount of GFP (peak), and the bound proteins 
pooled for each pH conditions. 
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Gel fractions in each case look virtually identical, so either pH could be used without 
significant difference. Nevertheless, densitometry that determined relative protein concentration 
and GFP purity of each trial gave evidence that pH 6.2 was slightly more advantageous. Relative 
GFP purity in the pooled fractions was 21.5% and 18.7% for pH 6.2 and 6.0, respectively. A 
chromatogram from the pH 6.2 run is shown in Figure 5.5 (Remember that the GFP curve 
presented here was prepared as described in Figures 5.1 and 5.2. Labels of peak relative 
fluorescence after loading and during elution are given). 
Two additional trials were carried out to determine the initial salt concentration. Buffers 
at pH 6.2 contained either 50 or 100 mM NaCl were compared. GFP did not retain binding at 
100 mM, whereas all conditions were satisfactory at 50 mM (shown in Figure 5.6). 
 
 
Figure 5.5. Chromatogram of the AEX trial with pH 6.2, 0 M NaCl loading buffer.  
GFP assays (green points with connecting line) indicate that GFP had 5.1% breakthrough at the 
end of loading and eluted in a single peak. Total protein (blue line) indicated two elution peaks 
during salt gradient elution (red line). The second peak is indicative of residual DNA in the 
sample as no proteins were observed from these fractions via SDS-PAGE (not shown). 
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Figure 5.6. Chromatogram of the AEX trial with pH 6.2, 50 mM NaCl loading buffer.  
GFP assays (green points with connecting line) indicate that GFP had 16% breakthrough at the 
end of loading and eluted in a single peak. Total protein (blue line) indicated two elution peaks 
during salt gradient elution (black line). The second peak is indicative of residual DNA in the 
sample as no proteins were observed from these fractions via SDS-PAGE (not shown). 
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While GFPuv flow through was a bit higher than ideal for the 50 mM NaCl case (16%), 
the marginal increase in flow through would not detract from subsequent analysis of the bound 
protein pool. GFPuv desorbed from the column at the forefront of the first elution peak, which 
was anticipated from both prior results and column manufacturer literature stating that when 
proteins are loaded in buffers with a pH of 0.5 units more basic, they typically begin to elute at 
0.1 M NaCl. An SDS-PAGE gel of this purification (not shown) did not differ noticeably from 
the “pH 6.2” bands in Figure 5.4. Based on that outcome and the recommendation by GE to find 
optimal ionic strengths at increments of 0.05 M NaCl in a series of buffers, it was felt that pursuit 
of trials in the range of 0−50 mM would be of little consequence. 
5.2.2 Purification analysis and characterization of co-purifying proteins 
A schematic of the purification strategy is given in Figure 5.7. E. coli BL21 pellets were 
resuspended with HIC elution buffer (20 mM NaH2PO4, pH 7.2) and then adjusted to 1.5 M 
ammonium sulfate. The solution was incubated on ice prior to spin down of precipitated 
material, filtration, and column loading. Initial experiments on HiTrap Phenyl FF (low-
substitution) columns revealed that this procedure yielded adequate GFP retention. GFPuv 
breakthrough at the end of the loading phase, measured by the fluorescence exiting the column 
normalized to the cleared lysate, was 6% with 1.5 M ammonium sulfate. The elevated 
concentration resulted in significant precipitation of other strongly expressed proteins, easing 
binding competition with the target. This is more clearly illustrated in Figure 5.8, which shows 
sequential “cuts” of an ammonium sulfate precipitation (The lane labeled “IP” is the insoluble 
pellet centrifuged after sonication. Lanes 2 through 9 are labeled with molar concentration of 
ammonium sulfate.  The lane labeled “Sup.” is the resulting supernatant after precipitation with 
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1.5 M ammonium sulfate, and is representative of the loading material for the HIC step). Outer 
membran protein OmpF is labeled with an arrow in the figure. OmpF forms a homotrimeric 
porin that allows passive diffusion of ions and small molecules into the cell and was identified 
among those that were preferentially reduced prior to HIC column loading (confirmed by PMF; 
Mascot score 116, e- value 1.3e-6, 9 peptides with 33% sequence coverage).  
 
 
Figure 5.7. Schematic of the workflow used to purify un-tagged GFP and host proteins.  
The bacterial pellet was resuspended in HIC elution buffer (20 mM NaH2PO4, pH 7.2), 
sonicated, and then centrifuged to remove debris. The supernatant was adjusted with ammonium 
sulfate to 1.5 M, incubated on ice for 10 min, and then centrifuged again to remove precipitated 
protein. The remaining supernatant was loaded on the HIC column. After equilibration, bound 
proteins were eluted by decreasing ammonium sulfate gradient and buffer exchanged (20 mM 
Bis Tris, 50 mM NaCl, pH 6.2) prior to loading on the AEX column. Bound proteins were eluted 
with increasing NaCl gradient. Protein fractions from each step were saved for gel analysis. 
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Figure 5.8. Ammonium sulfate precipitation of proteins expressed in BL21 (DE3) pGFPuv.  
The “IP” lane shows proteins contained in the insoluble pellet (cell debris and inclusion body 
proteins). The following lanes show protein precipitated at their corresponding ammonium 
sulfate concentrations, known as “cuts” of the precipitation. The soluble protein (supernatant, 
labeled “Sup.” lane) after incubation with 1.5 M ammonium sulfate was the loading material for 
the HIC column. The arrow corresponds to outer membrane protein OmpF, which is a highly-
expressed host protein that was preferentially removed during precipitation. GFP is the 
prominent band aligned with the 28 kDa standard. 
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Proteins eluted from the HIC column were pooled, buffer exchanged, and applied to the 
AEX column. Initial trials on Q columns determined that an optimal loading buffer was 20 mM 
Bis-Tris, 50 mM NaCl at pH 6.2. GFPuv breakthrough was not detected during column loading 
as it was during optimization using complex lysate due to the fact that AEX is here used as the 
second column step. The preliminary trial runs were conducted without anticipating which order 
the columns would be used. Indeed, a purification using the reverse of the scheme presented here 
was conducted with inferior results and will be discussed in Section 5.5. 
Proteins recovered in all steps of the purification are illustrated in Figure 5.9. Co-
purifying proteins were confirmed by PMF and the most prominent bands are labeled by gene 
name. GroEL (57 kDa) and elongation factor Tu (43 kDa) are marked by arrows next to lane 4 
and are discussed later. To briefly review the methods used to generate the gel, soluble extract 
was loaded on the HIC column using a buffer containing 1.5 M ammonium sulfate, equilibrated, 
then eluted with a gradient down to 0 M. Fractions containing GFPuv were dialyzed against 
AEX buffer and 5 ml was loaded on the Q column at pH 6.2. Bound proteins were eluted with a 
20 CV linear salt gradient to 1 M. Lanes were loaded with 25 µg protein, except for lanes 7-9, 
which contained about 10 µg. Samples for the HIC flow through, and AEX flow through and 
first elution peak were prepared from TCA/DOC precipitated proteins. The accompanying 
process data is given in Table 5.1.  
 
  90 
 
Figure 5.9. SDS-PAGE of GFPuv purified by HIC-AEX.  
Protein fractions were taken from each step of the purification process, as illustrated in Figure 
5.7. Lanes are: MW, molecular weight ladder; IP, insoluble pellet; AS precip., protein 
precipitated by 1.5 M ammonium sulfate; Load, HIC load material; HIC flow through; HIC 
elution pool; Buffer Ex., protein pool after buffer exchange; AEX flow through; first AEX 
elution peak; second AEX elution peak. Arrows in HIC load lane correspond to GroEL (57 kDa) 
and elongation factor Tu (43 kDa). 
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Table 5.1. Relevant purification data for each downstream process. 
Purification Step Total Protein (mg) GFP (mg) Yield (%) Purity (%) Purification 
Fold 
HIC-AEX      
Soluble Extract 42 8.6 100 21 1 
HiTrap Phenyl FF 29 8.0 92 27 1.3 
Post-dialysis 4.5 1.9 --- 42 2.0 
HiTrap Q FF 2.4 1.6 84 66 3.2 
      
CEX      
Soluble Extract 47 8.8 100 19 1 
HiTrap SP FF 16 7.9 90 50 2.6 
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This scheme purified over-expressed GFPuv by 3.2-fold using non-affinity based 
matrices, noting that this is out of a maximum purification fold of 4.8. Overall GFPuv yield 
attained from the column steps was 77% and was purified to approximately 66% purity, 
determined by gel densitometry. Calculation of the process yield did not consider the HIC bound 
proteins that were dialyzed but not ultimately loaded on the Q column, as only five mL were 
used for the final column step; however when accounting for actual GFP loss during dialysis, 
overall yield was 55%. While my aim was not centered on yield optimization, other dialysis 
methods could have mitigated loss between column steps. Minor flow through in the HIC step 
and the GFPuv fraction pooling strategy contribute to diminishing the yield during 
chromatography, but overall the yield that I obtained is comparable to that reported for multi-
step non-affinity schemes.43 
Purification of a target protein to homogeneity using this or similar scheme, without 
further fine-tuning of operational or column conditions, would likely necessitate a third polishing 
column step. This presents an opportunity to improve efficiency using an approach that uses 
proteomic tools to suggest rational genetic modifications specifically advantageous for 
downstream processing. Thirteen proteins that co-eluted with GFPuv from the AEX column are 
presented in Table 5.2.  
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Table 5.2. Proteins that co-purified with GFPuv during purification via ammonium sulfate precipitation, HIC, and AEX. 











ileS Isoleucyl-tRNA synthetase 104231 5.66 P00956 11 10 92 
acnB Aconitate hydratase 2 93439 5.24 P36683 18 21 74 
pckA Phosphoenolpyruvate carboxykinase 59606 5.46 P22259 16 38 91 
pepD Aminoacyl-histidine dipeptidase 52882 5.20 P15288 9 19 74 
gltA Citrate synthase 47984 6.21 P0ABH7 6 12 57 
sucC Succinyl-CoA ligase [ADP-forming] subunit beta 41367 5.37 P0A836 13 34 96 
gcvT Aminomethyltransferase 40121 5.36 P27248 6 17 76 
talB Transaldolase B 35197 5.11 P0A870 8 33 84 
cysK Cysteine synthase A 34468 5.83 P0ABK5 9 41 70 
tsf Elongation factor Ts 30404 5.22 P0A6P1 7 25 83 
dapD Tetrahydrodipicolinate N-succinyltransferase 29873 5.56 P0A9D8 7 25 79 
gmhA Phosphoheptose isomerase 20802 5.97 P63224 5 22 67 
ahpC Alkyl hydroperoxide reductase subunit C 20748 5.03 P0AE08 4 32 77 
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Several of the identified proteins in the final pool were present in only small amounts. 
Included in this group are TCA cycle enzymes: aconitase B (acnB) catalyzes the reversible 
isomerization of citrate and isocitrate;152 the beta subunit of ADP-forming succinyl-coA ligase 
(sucC); and citrate synthase (gltA), which produces citrate and CoA from acetyl-CoA and 
oxaloacetate. Mutants lacking sucC and gltA are undesirable for biotechnology applications since 
they have been shown to produce elevated acetate levels.153, 154 Enzymes involved in amino acid 
biosynthesis are tetrahydrodipicolinate N-succinyltransferase (dapD), an enzyme involved in 
lysine synthesis via the diaminopimelate pathway; and cysteine synthase A (cysK), which 
converts O-acetylserine to cysteine and acetate. Others include the essential class I isoleucyl-
tRNA synthetase (ileS);155, 156 the T subunit of the glycine cleavage complex 
aminomethyltransferase (gcvT); transaldolase B (talB), important for balancing metabolite 
concentrations in the pentose-phosphate pathway and has been previously purified by 
ammonium sulfate precipitation and AEX;157 alkyl hydroperoxide reductase subunit C (ahpC); 
phosphoheptose isomerase (gmhA) that is involved in LPS biosynthesis; and elongation factor Ts 
(tsf), which associates with the EF-Tu-GDP complex at the ribosome and induces exchange of 
GDP to GTP.158 Nonessential proteins in this group total less than 8% of the final pool by 
densitometry; and thus knockout of such genes, if not detrimental to the cell, would not be 
expected to significantly enhance purification efficiency. 
Other gene products that provide opportunities for deletion are those that burden the 
purification scheme, but do not ultimately co-purify with the protein of interest. For column 
steps, for example, such proteins hinder target binding capacity without necessarily reducing 
final purity. Indeed, proteins bands of interest were identified regardless of where they appeared 
in the process. Here, clarification with ammonium sulfate prevented some such proteins from 
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burdening column steps. Outer membrane porin OmpF (~37 kDa) contributed significantly to the 
insoluble and soluble protein fractions, but was preferentially removed with ammonium sulfate, 
shown in Figure 5.8 and lane 3 of Figure 5.9. Based on this case, knockout of ompF may be 
desirable to ease the metabolic burden on a host expressing recombinant proteins at high levels. 
Although it was reported that mutants lacking OmpF have reduced susceptibility to β-lactam and 
tetracycline antibiotics, this was found at low concentrations (1-2 µg/mL ampicillin) relevant to 
natural environments and not at those used to provide selection pressure (50-100 µg/mL).159 
Based on this case, knockout of ompF may be desirable to ease the metabolic burden on a host 
expressing recombinant proteins at high levels. 
While knockout of ompF could be advantageous, its dramatic precipitation relative to the 
target prior to any column step nevertheless lends credence to use of this scheme that dissipates 
the burden of host protein removal over multiple non-affinity-based steps. This is also neatly 
illustrated by the separation of elongation factor Tu (EF-Tu, tufA) and chaperonin GroEL (groL) 
over both column operations. Shown in lanes 4-7 and 9 of Figure 5.9 are prominent bands of 43 
kDa and 57 kDa, associated with EF-Tu and GroEL respectively, which depicts their removal in 
both the flow through during HIC and elution in a peak distinct from the target during AEX (EF-
Tu/GroEL were confirmed by PMF; corresponding scores 92/83, e-values 3.4e-4/2.6e-3, 10/9 
peptides, 26%/18% sequence coverage). Their ultimate binding to the AEX column is 
unfortunate given the importance of GroEL and EF-Tu to protein folding and translation, 
respectively. Mutants deficient in groL are not viable and those deficient in tufA have a slow-
growth phenotype in complex media.160, 161 
A combined proteomic and host cell engineering approach offers the most significant 
gains in downstream processing efficiency by genetically removing the most burdensome co-
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eluting proteins. Phosphoenolpyruvate carboxykinase (PEPCK; encoded by pckA) and 
aminoacyl-histidine dipeptidase (PepD) were the prominent contaminants, accounting for about 
15% of co-eluting proteins by mass. PepD is a metallo-dipeptidase that acts on a broad spectrum 
of substrates with unblocked N termini, including unusual dipeptides like L-carnosine.162, 163 It 
has been hypothesized that a significant portion of PepD activity lies outside the cytoplasmic 
membrane, perhaps aiding the degradation of lengthy peptides for transport into the cell.164 E. 
coli posses many peptidases, however, and pepD-deficient mutants can still utilize a diverse 
array of peptides.162 PEPCK is a gluconeogenic enzyme that requires divalent cation(s) to 
catalyze the reversible decarboxylation and mononucleotide-dependent phosphorylation of 
oxaloacetate, yielding phosphoenolpyruvate (PEP), CO2, and the corresponding nucleoside 
diphosphate.165 PEPCK and PEP carboxylase, which catalyzes the reverse reaction, act at a 
critical node of carbon metabolism by maintaining the PEP:oxaloacetate ratio and concentrations 
of TCA intermediates.166 PEP carboxylase exclusively catalyzes the anaplerotic reaction from C3 
metabolites in E. coli. Inactivation of pckA has been shown by Yang et al. to cause a reciprocal 
drop in PEP carboxylation and increased carbon flux through glyoxylate shunt, replenishing 
TCA cycle intermediates, namely oxaloacetate.167 It was also noted that this flux pattern was 
similarly found in the low acetate producer BL21,168 and further that pckA mutants showed 
significantly increased biomass yields and reduced CO2 evolution rates compared with wild-type 
E. coli during slow growth in glucose-limited media.167 These reports lend credence to a 
plausible use for ∆pckA strains in biotechnology applications.  
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Given the strong presence of PEPCK and PepD in the co-purification pool and the prior 
findings discussed, there are grounds for further development of a ∆pckA ∆pepD strain 
intrinsically advantageous for purification of select recombinant products via HIC-AEX 
schemes. 
5.3 PURIFICATION OF ARG6-GFP BY CATION EXCHANGE 
CHROMATOGRAPHY 
As before, little process optimization was carried out for the CEX step. It was intended to use the 
minimal operating pH that ensured sufficient retention of the target while the vast majority of E. 
coli host proteins, carrying a net negative charge, flowed through. Analysis of co-purifying 
proteins could thus be applicable to a variety of elution strategies. Initial preparations included 
loading buffers at pH 5.5 and 6.0, but proved problematic with either residual arg6-GFPuv bound 
to the column after elution with high salt or less-than-desired retention, respectively. Soluble 
lysates were ultimately prepared in a loading buffer of 50 mM MES and adjusted to pH 5.7, the 
pI of untagged GFPuv. Lysozyme was not used in the sample preparation, anticipating its 
dominating presence in the CEX eluate (this was actually observed in preliminary experiments 
discussed later in section 5.4). Five CV of sample was passed through a 1 ml HiTrap SP FF 
column. Fluorescence detected arg6-GFPuv breakthrough of 8%; whereas lysate containing 
untagged GFPuv in the same conditions expectedly showed no target retention. Proteins were 
eluted with a 15 CV linear NaCl gradient to 1 M, followed by a step gradient to 2 M. No proteins 
were recovered in the subsequent step elution to 2 M in either case. Chromatograms that 
compare behavior of the native and arg6-GFPuv are presented in Figures 5.10 and 5.11. 
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Figure 5.10. Chromatogram of CEX of untagged GFPuv with loading at pH 5.7.  
GFP assays (green dots with connecting line) indicate that untagged GFP showed no column 
retention, flowing through the column during loading. 
 
 
Figure 5.11. Chromatogram of CEX of arg6-GFPuv with loading at pH 5.7.  
GFP assays (green dots with connecting line) indicate that arg6-GFP had 9% breakthrough at the 
end of loading and eluted in a single peaking during salt gradient elution (red line). 
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Proteins were sampled at each step in the process and fractionated by SDS-PAGE and 
presented in Figure 5.12, with corresponding purification data shown in Table 5.1. The target 
was purified to about 50% purity, a 2.6-fold refinement, at 90% yield. Note that while this CEX 
scheme did not outperform the HIC-AEX scheme, the column step was superior to either 
individual step in the prior strategy, presumably due to the endowed localized charge. The purity 
achieved may seem underwhelming in comparison to other studies where multiple steps were 
used,49 but the process yield compares very favorably to previous successful uses of this 
method.54 However, it is noted again this purification was intentionally not optimized for 
maximum performance. Though it was troubling to find a high amount of insoluble target protein 
production (lane 2), even more so than in the un-tagged strain cultured identically in spite of 
evidence that polyarginine tags improve solubility.169 This effect could possibly have been 
mitigated with the addition of NaCl during resuspension.56 The focus, however, was specifically 
on soluble host proteins that challenged the column step. Note that OmpF, in this case again 
highly expressed, flowed through the column under the given conditions (lane 4). Also found in 
the flow through are the characteristic bands of RNA polymerase β/ βʹ′ subunits (~155 kDa). 
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Figure 5.12. SDS-PAGE of arg6-GFPuv purification by CEX.  
Lanes were loaded with 25 µg protein. Lanes are: (1) molecular weight ladder, (2) insoluble 
pellet, (3) CEX load, (4) flow through, (5) wash fraction, (6) first elution peak, (7) elution peak 
containing arg6-GFPuv. Identified bands in the final lane correspond to the gene names on the 
right. 
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Eleven proteins confirmed to co-elute with arg6-GFPuv are presented in Table 5.3. Some 
lesser relevant contaminating proteins are lysyl-tRNA synthetase (lysS), bifunctional protein 
PutA (putA) is a proline catabolic enzyme and an autogenous transcriptional repressor of proline 
utilization genes,170 and an uncharacterized UPF0438 protein (yifE). Cysteine desulfurase (iscS) 
is also present. It acts in iron-sulfur clusters after assembly with scaffold homolog IscU and 
possibly has a role in regulation of genes associated with pyrimidine metabolism.171 Mutants 
deficient in iscS have been characterized to have a slow growth phenotype.172 
One prominent contaminating protein is trigger factor (tig). Trigger factor is a well-
studied ribosome-associated chaperone, binding to nascent peptides at the exit site, exhibits 
peptidyl-prolyl cis/trans isomerase activity, and play a role in Sec- and SRP-dependent protein 
export.173 While ∆tig strains have no obvious growth phenotype or increased protein aggregation, 
they must be compensated by the DnaK/J and GroEL/S systems;174, 175 therefore tig mutants are 
ill-suited for biotech applications that utilize over-expression of recombinant proteins. For 
further details, reviews can be consulted.173, 176 
As opposed to trigger factor, elongation factor 4 (lepA) is a good candidate for removal. 
It is a translational GTPase with an apparent ability to catalyze reverse translocation in vitro177 
and was thought to play a role in translation fidelity. Recent evidence, however, not only 
confirms prior reports that mutants lacking lepA exhibit no deleterious effect on growth rate,178 
but also suggests that its gene product does not contribute to translation fidelity.179 
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Table 5.3. Proteins that co-purified with arg6-GFPuv during purification by CEX. 











putA Bifunctional protein putA 143725 5.69 P09546 15 10 96 
lepA Elongation factor 4 66528 5.40 P60785 14 27 77 
lysS Lysyl-tRNA synthetase 57567 5.11 P0A8N3 10 18 88 
tig Trigger factor 48163 4.83 P0A850 9 22 70 
iscS Cysteine desulfurase 45061 5.94 P0A6B7 10 27 84 
sucC Succinyl-CoA ligase [ADP-forming] subunit beta 41367 5.37 P0A836 10 25 76 
rplC 50S ribosomal protein L3 22230 9.91 P60438 6 33 84 
rplF 50S ribosomal protein L6 18892 9.71 P0AG55 6 36 87 
rplI 50S ribosomal protein L9 15759 6.17 P0A7R1 5 28 87 
yifE UPF0438 protein yifE 13125 6.10 P0ADN2 7 56 81 
rplY 50S ribosomal protein L25 10687 9.60 P68919 6 70 65 
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Four out of the thirteen identified contaminants are 50S ribosomal proteins L3 (rplC), L6 
(rplF), L9 (rplI), and the particularly abundant L25 (rplY). Excluding GFPuv, L25 accounted for 
about a third of bound protein by densitometry. The former three are essential for E. coli cell 
viability,180-182 though L25 deserves further consideration. It was the first discovered 
representative the CTC (catabolite controlled) family in 1972.183 Proteins of this class are 
associated with stress conditions and characteristically bind to the designated loop E region of 5S 
rRNA in the 50S subunit,184-186 a domain strictly conserved in bacteria187 and distinctive for 
consecutive non-Watson-Crick base pairs (i.e. the nucleotides are not entirely complementary).  
Indeed, evidence has shown that all CTC proteins posses a domain, homologous to L25, 
responsible for 5S binding at this site, their only known target for interaction.188, 189 Despite the 
wealth of biochemical, interaction, and structural studies, questions remain concerning their 
cellular function in bacteria and role in translation. L25, like others of the CTC class, is thought 
of as an evolutionary feature of translation exclusive to bacteria, and is hypothesized to have a 
possible role in ribosome recycling.190 In E. coli, cells survive knockout of L25 but exhibit 
inhibited growth and protein translation which could be recovered by L25 expression from 
plasmid;190 nevertheless such a strategy is unsuitable for biotechnology applications.  
For an alternative approach, it is necessary to discuss the conservation of residues among 
CTC proteins. Work by Stoldt,191 Wöhnert and colleagues,192 and Gongadze’s group 188, 193 has 
utilized sequence alignment of 300 CTC proteins across all bacterial taxons to reveal conserved 
residues. Given the specific nature in which CTC proteins associate with the ribosome, they have 
surprisingly low sequence homology and only five strictly conserved residues. In L25, these are 
R9, R21, Y31, H88 and D90. It has been shown that these residues interact primarily with the 
phosphoribose backbone via hydrogen bonding, inaccessible to the solvent. Importantly, this 
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low-homology characteristic differs from typical proteins with sequence-specific DNA-binding, 
in which protein side chains and the nucleotides with which they interact are highly conserved 
among bacterial species.193 Mutation experiments with TL5, an L25 homologue in Thermus 
thermophilus, found that alanine substitution of non-conserved hydrogen bond-forming residues 
does not significantly attenuate 5S rRNA complex formation.189, 194 This is attributed to the 
accessibility the residues have with the solvent. While these substitutions may exact an entropic 
cost, it is compensated by new hydrogen bonding with the solvent; whereas with any single 
conserved, inaccessible residue, such mutation does not allow complex formation.189 
In contrast to affinity techniques, CEX interaction is based on electrostatic charge. 
Modifications of proteins that result in reduction of retention are thus not likely limited to one or 
two select residues, especially with large proteins. In contrast, E. coli L25 is a good candidate for 
residue modification due to its small size and few instances of consecutive positively charged 
residues. In yet unpublished results, our collaborators have used this surface modification 
strategy to substitute two histidines of triosephosphate isomerase (TPI) to eliminate retention on 
immobilized metal columns (Beitle, personal communication). Humphreys et al. introduced 
surface mutations and fused six aspartic acid residues to the C-terminus of PhoS/PstS protein, 
substantially shifting its ‘functional pI’ to prevent its co-elution with a recombinant Fab’ 
fragment.55 It is hypothesized that an altered L25 with substitutions to some of its non-conserved 
lysine and arginine residues, particularly consecutive arginines 18 and 19 and/or lysines 68, 71 
and 73, would have vastly reduced affinity for CEX matrices. Further, use of a host strain 
deficient in lepA and with altered L25 could have significant, intrinsic advantages for CEX 
separation of polyarginine tagged proteins.  
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5.4 CONCLUSIONS 
Reported in this study are the preliminary efforts to integrate rational upstream host design and 
downstream efficiency using proteomic tools to evaluate co-purifying host proteins that most 
significantly burden two non-affinity based processes. Phosphoenolpyruvate carboxykinase and 
peptidase D dominated non-target binding after HIC-AEX, accounting for almost half of the host 
protein that co-eluted with GFPuv. Previous inactivation of pckA and pepD has not revealed 
evidence for growth or expression-associated problems that concern biotechnology applications. 
L25 may alternatively be modified to lessen or eliminate its column burden to significantly 
improve target purity. This analysis serves an expressed need for process integration based on 
improved knowledge on physicochemical properties of relevant host proteins, in an effort to rival 
efficiency of affinity separation methods with inexpensive resins.  As this knowledge expands 
with purification of other model proteins, host strains more robust to contamination can be 
developed. 
5.5 SUPPLEMENTAL FINDINGS 
Some of the results obtained during the development of the research described herein were 
thought to be secondary to the more cohesive story. They are, nonetheless, interesting and should 
be discussed here, starting with bioseparation via CEX. 
Preliminary work with CEX was carried out using lysate derived from stains containing 
no plasmids. Without monitoring the binding and elution behavior of a target protein, buffer 
parameters could not be optimized as described above. Instead, the buffers purposefully 
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mimicked those reported by Sassenfeld and Brewer in their CEX purification of polyarginine-
tagged human recombinant urogastrone, which was 50 mM MES, pH 5.5.49 Twenty CV of lysate 
prepared in this buffer were applied to a HiTrap SP FF column, equilibrated with buffer, then 
eluted stepwise to 200 mM and 1 M NaCl. The chromatogram is presented in Figure 5.13. 
Proteins eluted during the second step were pooled and subjected to 2D-PAGE, shown in Figure 
5.14 with labels denoting protein spots analyzed by PMF. It is immediately noticeable from the 
gel image that a group of low molecular weight, high pI proteins has amassed at the lower right 
corner. The largest contributor to this cluster was identified as lysozyme, which as noted in 
Table 5.4 is the list of co-purifying proteins identified from this and a subsequent two-
dimensional gel produced with the same protein pool. Preceding sonication, ten mg of chicken 
egg white lysozyme had customarily been added to the resolubilization buffer to hydrolyze 
peptidoglycans in the bacterial cell wall to encourage release of cellular proteins. With a pI of 
9.37, it follows that it would bind the CEX matrix and thus hinder interaction between the matrix 
and host proteins I seek to identify. This result formed the basis for my decision to forego use of 
lysozyme in the preparation of lysate in the prior chapter.  
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Figure 5.13. Chromatogram of CEX purification of BL21 cellular proteins.  
Total protein (blue line) indicates the elution of two peaks that correspond with step increases of 
NaCl (red line). 
 
 
Figure 5.14. 2D-PAGE of BL21 proteins in the second elution peak of the CEX purification. 
Protein spots were excised from the gel for identification by MALDI-TOF-MS. 
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Table 5.4. BL21 cellular proteins captured by CEX that correspond to the gel in Figure 5.13. 











1 rpsA 30S ribosomal protein S1 61121 4.89 P0AG67 14 32 100 
2 tig Trigger factor 48163 4.83 P0A850 19 55 129 
4/10 infB Translation factor IF-2 97290 5.80 P0A705 22 25 114 
5 secA Protein translocase subunit 101959 5.43 P10408 13 14 66 
7 lepA Elongation factor 4 66528 5.40 P60785 8 14 58 
8 tufA Elongation factor Tu 43256 5.30 P0CE47 17 51 167 
9 accA ACCase subunit alpha 35219 5.76 P0ABD5 10 40 93 
13 rplI 50S ribosomal protein L9 15759 6.17 P0A7R1 11 83 155 
15 LYZ Lysozyme C 16228 9.37 P00698 7 48 76 
16 rplF 50S ribosomal protein L6 18892 9.71 P0AG55 6 38 92 
17 proQ ProP effector 25877 9.66 P45577 13 59 117 
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 Several of the contaminants listed in Table 5.4 would later appear in the CEX 
purification of arg6-GFPuv such as elongation factor 4 (lepA), trigger factor (tig), and 50S 
ribosomal proteins L6 and L9. Others including the abundant 30S ribosomal protein S1 and 
elongation factor Tu (tufA) were curiously not detected in the later experiments. If they were 
present in the elution peak not containing arg6-GFPuv and could not be confirmed by PMF, 
perhaps they could be detected by more sensitive mass spectrometry techniques. Alternatively, 
the genes that express those proteins may be severely down regulated in the presence of a 
plasmid-encoded recombinant protein. A comparative technique such as DIGE could provide 
that answer. 
Regarding the purification of untagged-GFPuv by sequential column steps, it is 
worthwhile to discuss an alternative procedure that was pursued. Before protein capture and 
identifications were made, the modest optimization of column parameters was performed 
independently as though either AEX or HIC would be used as the initial capture step. Indeed the 
preferred scheme was compared with its reverse (i.e. AEX preceding HIC). During the ion 
exchange step, the five 1-mL fractions containing GFP were dialyzed overnight in HIC elution 
buffer (containing no ammonium sulfate) and then adjusted to 1.5 M before removal of 
precipitate material by filtration an HIC column loading. The chromatogram of this HIC step is 
presented in Figure 5.15. Note the scale of the total protein axis on the left. After dialysis and 
salt adjustment, a minute amount of total protein was ultimately applied to the column, of which 
only about a fifth flowed directly through the column. In these runs, selectivity was lacking when 
compared to the precipitation-HIC-AEX scheme. This is further supported by the SDS-PAGE 
gel of the final protein pool (Figure 5.16), here shown next to the final pool presented in section 
5.2 for the preferred protocol. 
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Figure 5.15. Chromatogram of HIC of proteins fractions containing GFP derived by AEX.  
GFP assays (green points with connecting line) indicates maximum column retention with 





Figure 5.16. Comparison of final protein pools between alternative non-affinity schemes.  
The first lane shows proteins captured by ammonium sulfate precipitation, hydrophobic 
interaction and anion exchange chromatography. The proteins in the second lane were captured 
by anion exchange, precipitation, and then hydrophobic interaction chromatography. 
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The difference in final GFP purity is immediately evident in the gel figure. Densitometry 
analysis of the gel lane showed that GFP was 19% pure, well below the 66% purity achieved in 
the other method. While some target loss was undoubtedly experienced in the dialysis and salt 
adjustment steps, this only speaks to the ineffective nature of using HIC second. Here, 
ammonium sulfate precipitation is practically not even utilized since it is being applied to only 
about five mL of dilute protein solution. In the former method, precipitation selects against much 
of the full composition of cell lysate, allowing better resolution in the subsequent column steps. 
This finding is consistent with a basic principle in protein purification: clarifying steps such as 
precipitation that are characteristically high yield, high capacity and lower resolution should be 
performed early, if not first, in a purification strategy. 
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6.0  CONSIDERATIONS FOR FUTURE WORK 
As discussed in the introductory chapter, the elution behavior of bacterial proteins during IMAC 
has been an area of study in our group for more than a decade. The experiments described here 
have yielded some important findings: (1) I demonstrated that knockout of select, nonessential 
bacterial genes that encode process-related impurities can improve final purity of a recombinant 
protein; (2) at low recombinant expression levels, host proteins such as CAP and chaperonins 
like SlyD become problematic in IMAC even under high imidazole conditions; (3) at high 
recombinant expression levels, most cellular contaminants are not relevant with high imidazole 
loading, in fact only CAP measurably contributed to the impurity in my case; and (4) specific 
CAP histidine residues can be substituted to eliminate its affinity for immobilized nickel even 
with low imidazole concentration during loading and without detriment to its cellular function. I 
may then reasonably suggest that further work in this area calls for chromosomal alteration of 
CAP and demonstration of improved downstream purification of other plasmid-expressed model 
proteins. Beyond such results, one additional worthwhile frontier in the pursuit of a host strain 
truly optimized for IMAC purification would be one that overcomes the challenge presented by 
SlyD. As an important foldase with a large histidine-rich C-terminal domain, a strategy that 
specifically addresses SlyD binding to nickel IMAC without additional column/polishing steps 
will be elusive.  
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Development of multi-knockout strains such as those proposed for the nonaffinity-based 
purifications is likely not a suitable direction at this stage. Attempting to demonstrate effective 
use of such strains would first necessitate intensive genetic manipulation and sequence 
confirmations over multiple months. Perhaps a more efficient use of resources would be to focus 
on strain robustness by varying culturing conditions/methods and expression of differing model 
proteins. The resulting identified impurities would allow design of strains with innate 
downstream efficiency that are more robust to fluctuations in culturing or column parameters.  
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APPENDIX 
STRAINS, PLASMIDS, PRIMERS AND PROBES 
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Table A.1. E. coli strains and plasmids used in this work. 
Strains/Plasmids Description Source 
E. coli Strains   
BL21 (DE3) High expression; encodes T7 RNA polymerase 
under the control of the lacUV5 promoter 
Stratagene 
DH5α Cloning; plasmid amplification Stratagene 
TOP10 Cloning; Site-directed mutagenesis Invitrogen 
BL21 General cloning; template for knockout experiments Stratagene 
ΔcyoA Mutant deficient in cyoA This study 
ΔcyoA_yfbG Mutant deficient in cyoA and yfbG This study 
ΔcyoA_yfbG_adhP Mutant deficient in cyoA, yfbG and adhP This study 
    
Plasmids   








pGFPuv pUC backbone. Carries a variant of GFP. IPTG 
inducible vector. Confers ampicillin resistance. 
Clontech 
pHis6-GFP Carries GFPuv with six histidines at the N-terminus. 
Confers ampicillin resistance. 
This study 
pWHHHPH-GFP Carries GFPuv with a WHHHPH tag at the N-
terminus. Confers ampicillin resistance. 
This study 
pWTcrp Carries wild-type crp. Confers ampicillin resistance. This study 
pH17Acrp Carries crp with the H17A substitution. Confers 
ampicillin resistance. 
This study 
pH19Ycrp Carries crp with the H19Y substitution. Confers 
ampicillin resistance. 
This study 
pH17A-H19Ycrp Carries crp with the H17A and H19Y substitutions. 
Confers ampicillin resistance. 
This study 
pH17A-H19Y-K52Ncrp Carries crp with the H17A, H19Y, K52N 
substitutions. Confers ampicillin resistance. 
This study 
pArg6-GFP Carries GFPuv with six arginines at the N-terminus. 
Confers ampicillin resistance. 
Gift from 
Beitle 
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Table A.2. Primers used in this work. 
Primers a Sequence b Nucleotide location 








yfbG F1 5-ATATGGGATGCCTCGGTATTGAAGCCCTGCTGGCTGC 
CGGTTACGAAATTATTAACCCTCACTAAAGGGCG-3 
2366089-2366138 
yfbG R1 5-CGCAGGAAGAAATCCAGCGTTTCGTCGATGGTTTCCT 
GCATATCAATTTTTAATACGACTCACTATAGGGCTC-3 
2367963-2368012 








cyoA F2 5- GGGATGGTTGTCATTATTTGCA-3   Complement 
(450784-450805) 
cyoA R2 5-GGGCGGATTCCGCGTGGCTC-3 Complement 
(449863-449882) 
yfbG F2 5- GCCTACCACGATATGGGATG-3   2366079-2336098 
yfbG R2 5- CCGTAAGATCAACGGTGCGCAG-3 2368008-2368029 
adhP F2 5-ATGAAGGCTGCAGTTGTTACG-3   Complement 
(1551842-1551862) 
adhP R2 5-GTGACGGAAATCAATCACCATG-3   Complement 
(1550855-1550876) 









WTcrp F 5-GGCATATGGTGCTTGGCAAACCGC-3 N/A 
WTcrp R 5-CCGGATCCTTAACGAGTGCCGTAAAC-3 N/A 
H17Acrp F 5-CGACTCTCGAATGGTTCTTGTCTGCCTGCC 
ACATTCATAAGTACCCATC-3 
N/A 













a. F indicates the forward primers, and R indicates reverse primers. 
b. Underlined sequences were PCR primers for amplification of FRT-PGK-gb2-neo-FRT 
cassette. 
c. The sequence of Kan F was located in the kanamycin cassette. 
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Table A.3. Southern blot probes used in this work. 
Southern blot 
Probes Primers Nucleotide location  Size 
F3 5-TGGCTGTTGGTTTCGCCTGG-3   Complement 
(450634-450653) 
cyoA 





F3 5-CCGCTGTGGGTGGAACGC-3 2366253-2366270 yfbG 
R3 5-CGCGCAGCAG GCGTTCTG-3 2367055-2367072 
 
820 bp 
F3 5-CCGGCGTAATTCTGGGCC-3   Complement 
(1551691-1551708) 
adhP 
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